Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,30101556,Bioavailability,Bioavailability of oral LTG was approximately 74% and did not differ by age.,Lamotrigine pharmacokinetics following oral and stable-labeled intravenous administration in young and elderly adult epilepsy patients: Effect of age. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30101556/),%,74,3601,DB00555,Lamotrigine
,30101556,clearance,LTG clearance was 27.2% lower in elderly than in young patients (1.80 L/h for a 70-kg patient).,Lamotrigine pharmacokinetics following oral and stable-labeled intravenous administration in young and elderly adult epilepsy patients: Effect of age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30101556/),[l] / [h],1.80,3602,DB00555,Lamotrigine
,12545490,recovery,The average recovery was 93.78% and the standard deviation was 2.66%.,[Determination of lamotrigine in the serum and study on pharmacokinetics in rabbits by RP-HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12545490/),%,93.78,4373,DB00555,Lamotrigine
,12545490,Cmax,"The concentration-time curve of lamotrigine in rabbits fitted to a two compartment model, in which Cmax was 9.34 micrograms/mL, t1/2(Ke) was 8.78 h, and CL/f(s) was 0.69 L/h.",[Determination of lamotrigine in the serum and study on pharmacokinetics in rabbits by RP-HPLC]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12545490/),[μg] / [ml],9.34,4374,DB00555,Lamotrigine
,12545490,t1/2(Ke),"The concentration-time curve of lamotrigine in rabbits fitted to a two compartment model, in which Cmax was 9.34 micrograms/mL, t1/2(Ke) was 8.78 h, and CL/f(s) was 0.69 L/h.",[Determination of lamotrigine in the serum and study on pharmacokinetics in rabbits by RP-HPLC]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12545490/),h,8.78,4375,DB00555,Lamotrigine
,12545490,CL/f(s),"The concentration-time curve of lamotrigine in rabbits fitted to a two compartment model, in which Cmax was 9.34 micrograms/mL, t1/2(Ke) was 8.78 h, and CL/f(s) was 0.69 L/h.",[Determination of lamotrigine in the serum and study on pharmacokinetics in rabbits by RP-HPLC]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12545490/),[l] / [h],0.69,4376,DB00555,Lamotrigine
,19645218,serum concentrations,LTG serum concentrations were increased significantly from 4.67 +/- 3.66 and 9.56 +/- 5.27 microg/ml by concomitant administration of VPA.,Lamotrigine and valproate pharmacokinetics interactions in epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19645218/),[μg] / [ml],4.67,7483,DB00555,Lamotrigine
,19645218,serum concentrations,LTG serum concentrations were increased significantly from 4.67 +/- 3.66 and 9.56 +/- 5.27 microg/ml by concomitant administration of VPA.,Lamotrigine and valproate pharmacokinetics interactions in epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19645218/),[μg] / [ml],9.56,7484,DB00555,Lamotrigine
,24240511,oral clearance (CL/F),"Based on the final model, the estimated LTG oral clearance (CL/F) for a typical patient weighing ≤25 kg, >25 to <60 kg or ≥60 kg who was concomitantly treated with CBZ was estimated to be 3.28, 4.23, or 7.15 l/h, respectively.",Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients--nonlinear mixed effects modelling approach. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24240511/),[l] / [h],3.28,10753,DB00555,Lamotrigine
,24240511,oral clearance (CL/F),"Based on the final model, the estimated LTG oral clearance (CL/F) for a typical patient weighing ≤25 kg, >25 to <60 kg or ≥60 kg who was concomitantly treated with CBZ was estimated to be 3.28, 4.23, or 7.15 l/h, respectively.",Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients--nonlinear mixed effects modelling approach. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24240511/),[l] / [h],4.23,10754,DB00555,Lamotrigine
,24240511,oral clearance (CL/F),"Based on the final model, the estimated LTG oral clearance (CL/F) for a typical patient weighing ≤25 kg, >25 to <60 kg or ≥60 kg who was concomitantly treated with CBZ was estimated to be 3.28, 4.23, or 7.15 l/h, respectively.",Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients--nonlinear mixed effects modelling approach. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24240511/),[l] / [h],7.15,10755,DB00555,Lamotrigine
,9579945,ratio of milk to plasma concentration,The ratio of milk to plasma concentration was 0.6 2 weeks after delivery and the plasma concentration in the breast-fed child was 25% of the mother's plasma levels.,Lamotrigine in pregnancy and lactation: a case report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579945/),,0.6,11205,DB00555,Lamotrigine
,9056048,"t1/2,z","For lamotrigine, there were no significant differences in Cmax, tmax, AUC, t1/2,z, CL/F and amount excreted in urine although t1/2,z tended to be longer for the renal failure group with a mean (+/-s.d.) of 35.9 +/- 10.7 h vs 27.8 +/- 4.3 h for the control group.",Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056048/),h,35.9,14331,DB00555,Lamotrigine
,9056048,"t1/2,z","For lamotrigine, there were no significant differences in Cmax, tmax, AUC, t1/2,z, CL/F and amount excreted in urine although t1/2,z tended to be longer for the renal failure group with a mean (+/-s.d.) of 35.9 +/- 10.7 h vs 27.8 +/- 4.3 h for the control group.",Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056048/),h,27.8,14332,DB00555,Lamotrigine
,8764817,elimination half-life (t1/2),"The median elimination half-life (t1/2) in patients receiving concomitant valproate (VPA) was 43.3 h; in patients receiving carbamazepine (CBZ) and/or phenobarbital (PB), it was 14.1 h; and in patients receiving both VPA and CBZ/ PB or other antiepileptic drugs (AEDs), it was 28.9 h.",Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8764817/),h,43.3,15735,DB00555,Lamotrigine
,8764817,elimination half-life (t1/2),"The median elimination half-life (t1/2) in patients receiving concomitant valproate (VPA) was 43.3 h; in patients receiving carbamazepine (CBZ) and/or phenobarbital (PB), it was 14.1 h; and in patients receiving both VPA and CBZ/ PB or other antiepileptic drugs (AEDs), it was 28.9 h.",Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8764817/),h,14.1,15736,DB00555,Lamotrigine
,8764817,elimination half-life (t1/2),"The median elimination half-life (t1/2) in patients receiving concomitant valproate (VPA) was 43.3 h; in patients receiving carbamazepine (CBZ) and/or phenobarbital (PB), it was 14.1 h; and in patients receiving both VPA and CBZ/ PB or other antiepileptic drugs (AEDs), it was 28.9 h.",Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8764817/),h,28.9,15737,DB00555,Lamotrigine
,11213851,relative bioavailability (F,The relative bioavailability (F = AUC(rectal)/AUC(oral)) was 0.52 +/- 0.23 (SD).,Relative bioavailability of lamotrigine chewable dispersible tablets administered rectally. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11213851/),,0.52,15817,DB00555,Lamotrigine
,16404803,Milk/maternal plasma concentration ratios,"Milk/maternal plasma concentration ratios close to 1 demonstrate extensive transfer to breast milk of many AEDs including ethosuximide, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate, and zonisamide.",Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breast-feeding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404803/),,1,16688,DB00555,Lamotrigine
,16890577,AUC ratios,"The median AUC ratios of lamotrigine 2N-glucuronide to lamotrigine on day 10 and day 20 were 0.57 (interquartile range, 0.39-0.75) and 1.12 (interquartile range, 0.87-1.31).",Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16890577/),,0.57,19276,DB00555,Lamotrigine
,16890577,AUC ratios,"The median AUC ratios of lamotrigine 2N-glucuronide to lamotrigine on day 10 and day 20 were 0.57 (interquartile range, 0.39-0.75) and 1.12 (interquartile range, 0.87-1.31).",Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16890577/),,1.12,19277,DB00555,Lamotrigine
,31404235,apparent volume of distribution (V/F),"The population estimates of the apparent volume of distribution (V/F) and apparent clearance (CL/F) were 12.7 L and 1.12 L/h, respectively.",Effects of Comedication and Genetic Factors on the Population Pharmacokinetics of Lamotrigine: A Prospective Analysis in Chinese Patients With Epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31404235/),l,12.7,23268,DB00555,Lamotrigine
,31404235,apparent clearance (CL/F),"The population estimates of the apparent volume of distribution (V/F) and apparent clearance (CL/F) were 12.7 L and 1.12 L/h, respectively.",Effects of Comedication and Genetic Factors on the Population Pharmacokinetics of Lamotrigine: A Prospective Analysis in Chinese Patients With Epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31404235/),[l] / [h],1.12,23269,DB00555,Lamotrigine
,16273133,C,"The following pharmacokinetic parameters were obtained for lamotrigine 5, 10, and 20 mg/kg, respectively: clearance of distribution from plasma to brain normalized with the volume of the brain, CL/V(h(-1)) = 4.64, 2.47, 2.40; brain-to-plasma partition coefficient, P = 0.40, 0.37, 0.34; first-order transfer rate constant from the brain to the plasma, K(h(-1)) = 11.68, 6.68, 5.96; single-pass mean transit time in the brain, MTT(h) = 0.086, 0.150, 0.168.",Neuropharmacokinetic characterization of lamotrigine after its acute administration to rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273133/),1/[h],4,24118,DB00555,Lamotrigine
,1817959,half life,"Mean half life (13.5 h), volume of distribution (1.36 l/kg) and clearance (1.27 ml/min/kg) were similar to previously reported results and did not change with increasing dose.",Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1817959/),h,13.5,24905,DB00555,Lamotrigine
,1817959,volume of distribution,"Mean half life (13.5 h), volume of distribution (1.36 l/kg) and clearance (1.27 ml/min/kg) were similar to previously reported results and did not change with increasing dose.",Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1817959/),[l] / [kg],1.36,24906,DB00555,Lamotrigine
,1817959,clearance,"Mean half life (13.5 h), volume of distribution (1.36 l/kg) and clearance (1.27 ml/min/kg) were similar to previously reported results and did not change with increasing dose.",Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1817959/),[ml] / [kg·min],1.27,24907,DB00555,Lamotrigine
,29578646,terminal half-life,"Lamotrigine serum concentrations peaked 2.5 hours postdose, with a mean terminal half-life of 36.8 hours.","Pharmacokinetics, Safety, and Tolerability of Lamotrigine Chewable/Dispersible Tablet Following Repeat-Dose Administration in Healthy Chinese Volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29578646/),h,36.8,26368,DB00555,Lamotrigine
,29578646,apparent lamotrigine oral clearance,The apparent lamotrigine oral clearance was 1577.88 mL/h.,"Pharmacokinetics, Safety, and Tolerability of Lamotrigine Chewable/Dispersible Tablet Following Repeat-Dose Administration in Healthy Chinese Volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29578646/),[ml] / [h],1577.88,26369,DB00555,Lamotrigine
,29578646,accumulation ratios,"The accumulation ratios (day 14 vs day 1) were 2.53 and 2.58 for area under the curve and peak concentration, respectively.","Pharmacokinetics, Safety, and Tolerability of Lamotrigine Chewable/Dispersible Tablet Following Repeat-Dose Administration in Healthy Chinese Volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29578646/),,2.53,26370,DB00555,Lamotrigine
,29578646,accumulation ratios,"The accumulation ratios (day 14 vs day 1) were 2.53 and 2.58 for area under the curve and peak concentration, respectively.","Pharmacokinetics, Safety, and Tolerability of Lamotrigine Chewable/Dispersible Tablet Following Repeat-Dose Administration in Healthy Chinese Volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29578646/),,2.58,26371,DB00555,Lamotrigine
,29169113,flow rate,"Separation was performed on a Hypersil GOLD C18 column by isocratic elution using acetonitrile: 10mM ammonium acetate solution (90:10, v/v) as mobile phase at a flow rate of 0.3mL/min.",A rapid and simple HPLC-MS/MS method for the simultaneous quantification of valproic acid and its five metabolites in human plasma and application to study pharmacokinetic interaction in Chinese epilepsy patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29169113/),[ml] / [min],0.3,27229,DB00555,Lamotrigine
,29341900,polydispersity index,"The nanoparticles prepared using PLCL with monomers' ratio of 25:75, had particle size value of 125 nm, polydispersity index value of 0.184, zeta potential value of -39 mV and encapsulation efficiency value of 99%, was selected to study their efficacy to deliver the drug to the brain.","Lamotrigine loaded poly-ɛ-(d,l-lactide-co-caprolactone) nanoparticles as brain delivery system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29341900/),,0.184,33580,DB00555,Lamotrigine
,29341900,zeta potential,"The nanoparticles prepared using PLCL with monomers' ratio of 25:75, had particle size value of 125 nm, polydispersity index value of 0.184, zeta potential value of -39 mV and encapsulation efficiency value of 99%, was selected to study their efficacy to deliver the drug to the brain.","Lamotrigine loaded poly-ɛ-(d,l-lactide-co-caprolactone) nanoparticles as brain delivery system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29341900/),mv,-,33581,DB00555,Lamotrigine
,29341900,zeta potential,"The nanoparticles prepared using PLCL with monomers' ratio of 25:75, had particle size value of 125 nm, polydispersity index value of 0.184, zeta potential value of -39 mV and encapsulation efficiency value of 99%, was selected to study their efficacy to deliver the drug to the brain.","Lamotrigine loaded poly-ɛ-(d,l-lactide-co-caprolactone) nanoparticles as brain delivery system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29341900/),mv,39,33582,DB00555,Lamotrigine
,29341900,encapsulation efficiency,"The nanoparticles prepared using PLCL with monomers' ratio of 25:75, had particle size value of 125 nm, polydispersity index value of 0.184, zeta potential value of -39 mV and encapsulation efficiency value of 99%, was selected to study their efficacy to deliver the drug to the brain.","Lamotrigine loaded poly-ɛ-(d,l-lactide-co-caprolactone) nanoparticles as brain delivery system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29341900/),%,99,33583,DB00555,Lamotrigine
,10528929,maximum plasma concentration (Cmax),"The mean maximum plasma concentration (Cmax), volume of distribution (Vd/F), and oral body clearance (Cl/F) for LTG (+/- SD) during pregnancy were 7.63+/-2.46 microg/ml 1.74+/-0.29 L/kg, and 0.19+/-0.04 L/h/kg, respectively.",Effects of pregnancy on the pharmacokinetics of lamotrigine in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10528929/),[μg] / [ml],7.63,35497,DB00555,Lamotrigine
,10528929,volume of distribution (Vd/F),"The mean maximum plasma concentration (Cmax), volume of distribution (Vd/F), and oral body clearance (Cl/F) for LTG (+/- SD) during pregnancy were 7.63+/-2.46 microg/ml 1.74+/-0.29 L/kg, and 0.19+/-0.04 L/h/kg, respectively.",Effects of pregnancy on the pharmacokinetics of lamotrigine in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10528929/),[l] / [kg],1.74,35498,DB00555,Lamotrigine
,10528929,oral body clearance (Cl/F),"The mean maximum plasma concentration (Cmax), volume of distribution (Vd/F), and oral body clearance (Cl/F) for LTG (+/- SD) during pregnancy were 7.63+/-2.46 microg/ml 1.74+/-0.29 L/kg, and 0.19+/-0.04 L/h/kg, respectively.",Effects of pregnancy on the pharmacokinetics of lamotrigine in dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10528929/),[l] / [h·kg],0.19,35499,DB00555,Lamotrigine
>,12959634,bioavailability,The bioavailability of the oral formulation of oxcarbazepine is high (>95%).,Clinical pharmacokinetics of oxcarbazepine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),%,95,36869,DB00555,Lamotrigine
,12959634,plasma protein binding,The plasma protein binding of MHD is about 40%.,Clinical pharmacokinetics of oxcarbazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),%,40,36870,DB00555,Lamotrigine
,12959634,Elimination half-lives,Elimination half-lives in healthy volunteers are 1-5 hours for oxcarbazepine and 7-20 hours for MHD.,Clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),h,1-5,36871,DB00555,Lamotrigine
,12959634,Elimination half-lives,Elimination half-lives in healthy volunteers are 1-5 hours for oxcarbazepine and 7-20 hours for MHD.,Clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),h,7-20,36872,DB00555,Lamotrigine
,11360028,T1/2,"Lamotrigine half-life (T1/2) and oral clearance (Cl/F) values were significantly lower and significantly higher, respectively, in patients comedicated with enzyme inducers than in those receiving valproic acid (T1/2 = 8.1 vs.",Single-dose pharmacokinetics of lamotrigine in children: influence of age and antiepileptic comedication. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360028/),,8.1,38250,DB00555,Lamotrigine
,11360028,Cl/F,"41.7 hours respectively, P < 0.001; Cl/F = 0.11 vs. 0.04 L/h per kg respectively, P < 0.005, geometric means), whereas Cmax and Tmax values were comparable in the two groups.",Single-dose pharmacokinetics of lamotrigine in children: influence of age and antiepileptic comedication. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360028/),[l] / [h·kg],0.11,38251,DB00555,Lamotrigine
,11360028,Cl/F,"41.7 hours respectively, P < 0.001; Cl/F = 0.11 vs. 0.04 L/h per kg respectively, P < 0.005, geometric means), whereas Cmax and Tmax values were comparable in the two groups.",Single-dose pharmacokinetics of lamotrigine in children: influence of age and antiepileptic comedication. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360028/),[l] / [h·kg],0.04,38252,DB00555,Lamotrigine
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1404,43042,DB00555,Lamotrigine
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1374,43043,DB00555,Lamotrigine
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1400,43044,DB00555,Lamotrigine
,18781906,trough levels,"Mean trough levels of imatinib were reduced up to 2.9-fold (477 ng/ml, CV 70%) in patients treated with EIAEDs.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],477,43045,DB00555,Lamotrigine
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],240,43046,DB00555,Lamotrigine
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],351,43047,DB00555,Lamotrigine
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],356,43048,DB00555,Lamotrigine
,18503564,elimination half-life,"During repeated dosing, steady state is reached within 2 days, consistent with its elimination half-life of 6-10 h.",Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18503564/),h,6-10,45117,DB00555,Lamotrigine
,15695057,benefit index,"Likewise, the two-drug combination of 1:3 was also beneficial and is worth recommendation with benefit index amounting to 1.36.",Interaction between lamotrigine and felbamate in the maximal electroshock-induced seizures in mice: an isobolographic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15695057/),,1.36,45502,DB00555,Lamotrigine
,15695057,benefit index,Only the combination of 3:1 was neutral with a benefit index of 1.08.,Interaction between lamotrigine and felbamate in the maximal electroshock-induced seizures in mice: an isobolographic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15695057/),,1.08,45503,DB00555,Lamotrigine
,19014839,C(max),"The mean (SD) C(max) and T(max) of the test formulation of lamotrigine were 1.7 (0.3) microg/mL and 1.2 (0.9) hours, respectively.","Bioequivalence of generic lamotrigine 100-mg tablets in healthy Thai male volunteers: a randomized, single-dose, two-period, two-sequence crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19014839/),[μg] / [ml],1.7,51008,DB00555,Lamotrigine
,19014839,T(max),"The mean (SD) C(max) and T(max) of the test formulation of lamotrigine were 1.7 (0.3) microg/mL and 1.2 (0.9) hours, respectively.","Bioequivalence of generic lamotrigine 100-mg tablets in healthy Thai male volunteers: a randomized, single-dose, two-period, two-sequence crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19014839/),h,1.2,51009,DB00555,Lamotrigine
,19014839,C(max),"The mean (SD) C(max) and T(max) of the reference formulation of lamotrigine were 1.7 (0.3) microg/mL and 1.4 (1.0) hours, respectively.","Bioequivalence of generic lamotrigine 100-mg tablets in healthy Thai male volunteers: a randomized, single-dose, two-period, two-sequence crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19014839/),[μg] / [ml],1.7,51010,DB00555,Lamotrigine
,19014839,T(max),"The mean (SD) C(max) and T(max) of the reference formulation of lamotrigine were 1.7 (0.3) microg/mL and 1.4 (1.0) hours, respectively.","Bioequivalence of generic lamotrigine 100-mg tablets in healthy Thai male volunteers: a randomized, single-dose, two-period, two-sequence crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19014839/),h,1.4,51011,DB00555,Lamotrigine
,19014839,AUC(0-t),The mean (SD) AUC(0-t) was 67.1 (13.2) microg/mL x h(-1) for the test product and 66.4 (14.6) microg/mL x h(-1) for the reference product.,"Bioequivalence of generic lamotrigine 100-mg tablets in healthy Thai male volunteers: a randomized, single-dose, two-period, two-sequence crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19014839/),[ml·μg] / [h],67.1,51012,DB00555,Lamotrigine
,19014839,AUC(0-t),The mean (SD) AUC(0-t) was 67.1 (13.2) microg/mL x h(-1) for the test product and 66.4 (14.6) microg/mL x h(-1) for the reference product.,"Bioequivalence of generic lamotrigine 100-mg tablets in healthy Thai male volunteers: a randomized, single-dose, two-period, two-sequence crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19014839/),[ml·μg] / [h],66.4,51013,DB00555,Lamotrigine
,19014839,AUC(0-infinity),The mean (SD) AUC(0-infinity) was 74.9 (18.3) microg/mL x h(-1) for the test product and 74.3 (20.5) microg/mL x h(-1) for the reference product.,"Bioequivalence of generic lamotrigine 100-mg tablets in healthy Thai male volunteers: a randomized, single-dose, two-period, two-sequence crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19014839/),[ml·μg] / [h],74.9,51014,DB00555,Lamotrigine
,19014839,AUC(0-infinity),The mean (SD) AUC(0-infinity) was 74.9 (18.3) microg/mL x h(-1) for the test product and 74.3 (20.5) microg/mL x h(-1) for the reference product.,"Bioequivalence of generic lamotrigine 100-mg tablets in healthy Thai male volunteers: a randomized, single-dose, two-period, two-sequence crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19014839/),[ml·μg] / [h],74.3,51015,DB00555,Lamotrigine
,19014839,t((1/2)),The mean (SD) t((1/2)) values were 35.0 (7.6) hours for the test product and 34.7 (7.6) hours for the reference product.,"Bioequivalence of generic lamotrigine 100-mg tablets in healthy Thai male volunteers: a randomized, single-dose, two-period, two-sequence crossover study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19014839/),h,35.0,51016,DB00555,Lamotrigine
,19014839,t((1/2)),The mean (SD) t((1/2)) values were 35.0 (7.6) hours for the test product and 34.7 (7.6) hours for the reference product.,"Bioequivalence of generic lamotrigine 100-mg tablets in healthy Thai male volunteers: a randomized, single-dose, two-period, two-sequence crossover study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19014839/),h,34.7,51017,DB00555,Lamotrigine
,17915637,Protein binding,"Protein binding, calculated from the concentrations in saliva was 57.5 +/-15.1% (mean +/- SD).",Comparison of plasma and saliva concentrations of lamotrigine in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17915637/),%,57.5,51671,DB00555,Lamotrigine
,11802095,CL/F,Population estimates of CL/F and V/F for lamotrigine generated in the final model were 2.14 +/- 0.81 L/h and 78.1 +/- 5.1 L/kg.,Population pharmacokinetics of lamotrigine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11802095/),[l] / [h],2.14,51797,DB00555,Lamotrigine
,11802095,V/F,Population estimates of CL/F and V/F for lamotrigine generated in the final model were 2.14 +/- 0.81 L/h and 78.1 +/- 5.1 L/kg.,Population pharmacokinetics of lamotrigine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11802095/),[l] / [kg],78.1,51798,DB00555,Lamotrigine
,17727739,trough serum concentrations,"After the LTG escalation to 200 mg/day, mean trough serum concentrations of 8.0 microg/mL did not differ significantly from the 9.5 microg/mL after VPA withdrawal or the 9.2 microg/mL after 4 weeks of monotherapy at 500 mg/day.",Conversion to lamotrigine monotherapy from valproate monotherapy in older adolescent patients with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17727739/),[μg] / [ml],8.0,53372,DB00555,Lamotrigine
,17727739,trough serum concentrations,"After the LTG escalation to 200 mg/day, mean trough serum concentrations of 8.0 microg/mL did not differ significantly from the 9.5 microg/mL after VPA withdrawal or the 9.2 microg/mL after 4 weeks of monotherapy at 500 mg/day.",Conversion to lamotrigine monotherapy from valproate monotherapy in older adolescent patients with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17727739/),[μg] / [ml],9.5,53373,DB00555,Lamotrigine
,17727739,trough serum concentrations,"After the LTG escalation to 200 mg/day, mean trough serum concentrations of 8.0 microg/mL did not differ significantly from the 9.5 microg/mL after VPA withdrawal or the 9.2 microg/mL after 4 weeks of monotherapy at 500 mg/day.",Conversion to lamotrigine monotherapy from valproate monotherapy in older adolescent patients with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17727739/),[μg] / [ml],9.2,53374,DB00555,Lamotrigine
,22171585,CL/F,"Eslicarbazepine CL/F was affected by bodyweight, dose of carbamazepine (D(CAR)) and co-administration of barbiturates or phenytoin (AED(PB)), as predicted by the equation CL/F = (2.36 + 0.00149 • D(CAR) + 1.41 • AED(PB)) • (weight/70)0.75, which means that CL/F is 2.36 L/h for a subject with a bodyweight of 70 kg and without concomitant carbamazepine and barbiturates/phenytoin.","Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22171585/),[l] / [h],2.36,53544,DB00555,Lamotrigine
,16313279,Vd,"The following parameters were obtained: Vd = 2.00 L/kg, k(abs) = 8.50 h(-1), k(el) = 0.025 h(-1), k(e0) = 3.75 h(-1), Emax = 100.0% (fixed), EC50 = 3.44 mg/L and gamma = 8.64.",Lamotrigine pharmacokinetic/pharmacodynamic modelling in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16313279/),[l] / [kg],2.00,55103,DB00555,Lamotrigine
,16313279,k(abs),"The following parameters were obtained: Vd = 2.00 L/kg, k(abs) = 8.50 h(-1), k(el) = 0.025 h(-1), k(e0) = 3.75 h(-1), Emax = 100.0% (fixed), EC50 = 3.44 mg/L and gamma = 8.64.",Lamotrigine pharmacokinetic/pharmacodynamic modelling in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16313279/),1/[h],8.50,55104,DB00555,Lamotrigine
,16313279,k(el),"The following parameters were obtained: Vd = 2.00 L/kg, k(abs) = 8.50 h(-1), k(el) = 0.025 h(-1), k(e0) = 3.75 h(-1), Emax = 100.0% (fixed), EC50 = 3.44 mg/L and gamma = 8.64.",Lamotrigine pharmacokinetic/pharmacodynamic modelling in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16313279/),1/[h],0.025,55105,DB00555,Lamotrigine
,16313279,k(e0),"The following parameters were obtained: Vd = 2.00 L/kg, k(abs) = 8.50 h(-1), k(el) = 0.025 h(-1), k(e0) = 3.75 h(-1), Emax = 100.0% (fixed), EC50 = 3.44 mg/L and gamma = 8.64.",Lamotrigine pharmacokinetic/pharmacodynamic modelling in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16313279/),1/[h],3.75,55106,DB00555,Lamotrigine
,16313279,Emax,"The following parameters were obtained: Vd = 2.00 L/kg, k(abs) = 8.50 h(-1), k(el) = 0.025 h(-1), k(e0) = 3.75 h(-1), Emax = 100.0% (fixed), EC50 = 3.44 mg/L and gamma = 8.64.",Lamotrigine pharmacokinetic/pharmacodynamic modelling in rats. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16313279/),%,100.0,55107,DB00555,Lamotrigine
,16313279,EC50,"The following parameters were obtained: Vd = 2.00 L/kg, k(abs) = 8.50 h(-1), k(el) = 0.025 h(-1), k(e0) = 3.75 h(-1), Emax = 100.0% (fixed), EC50 = 3.44 mg/L and gamma = 8.64.",Lamotrigine pharmacokinetic/pharmacodynamic modelling in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16313279/),[mg] / [l],3.44,55108,DB00555,Lamotrigine
,16313279,gamma,"The following parameters were obtained: Vd = 2.00 L/kg, k(abs) = 8.50 h(-1), k(el) = 0.025 h(-1), k(e0) = 3.75 h(-1), Emax = 100.0% (fixed), EC50 = 3.44 mg/L and gamma = 8.64.",Lamotrigine pharmacokinetic/pharmacodynamic modelling in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16313279/),,8.64,55109,DB00555,Lamotrigine
,16313279,plasma elimination half-life,"From these results, it can be stated that lamotrigine is extensively distributed through the body, its plasma elimination half-life is around 28 h and a lamotrigine plasma concentration of 3.44 mg/L is enough to protect 50% of the animals.",Lamotrigine pharmacokinetic/pharmacodynamic modelling in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16313279/),h,28,55110,DB00555,Lamotrigine
,16313279,plasma concentration,"From these results, it can be stated that lamotrigine is extensively distributed through the body, its plasma elimination half-life is around 28 h and a lamotrigine plasma concentration of 3.44 mg/L is enough to protect 50% of the animals.",Lamotrigine pharmacokinetic/pharmacodynamic modelling in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16313279/),mg,3.44,55111,DB00555,Lamotrigine
,34151674,Polydispersity index,LTG-PNPs exhibited % EE 71%; particle size 170.0 nm; Polydispersity index 0.191; zeta potential -16.60 mV.,"Lamotrigine loaded PLGA nanoparticles intended for direct nose to brain delivery in epilepsy: pharmacokinetic, pharmacodynamic and scintigraphy study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34151674/),,0.191,55133,DB00555,Lamotrigine
,34151674,zeta potential,LTG-PNPs exhibited % EE 71%; particle size 170.0 nm; Polydispersity index 0.191; zeta potential -16.60 mV.,"Lamotrigine loaded PLGA nanoparticles intended for direct nose to brain delivery in epilepsy: pharmacokinetic, pharmacodynamic and scintigraphy study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34151674/),m,16.60,55134,DB00555,Lamotrigine
,10212015,Oral clearance,Oral clearance was 0.64 +/- 0.26 ml/min/kg.,Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10212015/),[ml] / [kg·min],0.64,55253,DB00555,Lamotrigine
,10212015,apparent volume of distribution,The apparent volume of distribution was 1.50 +/- 0.51 L/kg.,Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10212015/),[l] / [kg],1.50,55254,DB00555,Lamotrigine
,10212015,half-life,"The mean half-life was 32 hours, similar to that in adults.",Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10212015/),h,32,55255,DB00555,Lamotrigine
,9429124,bioavailability,Lamotrigine is well absorbed with bioavailability approaching 100%.,Lamotrigine: pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429124/),%,100,55324,DB00555,Lamotrigine
,9429124,volume of distribution,The volume of distribution is between 1.25 and 1.47 L/kg and protein binding is about 55%.,Lamotrigine: pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429124/),[l] / [kg],1.25 and 1.47,55325,DB00555,Lamotrigine
,9429124,protein binding,The volume of distribution is between 1.25 and 1.47 L/kg and protein binding is about 55%.,Lamotrigine: pharmacokinetics. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429124/),%,55,55326,DB00555,Lamotrigine
,9429124,half-life,The half-life of lamotrigine is between 24.1 and 35 hours in drug naive adults but may be altered by enzyme inducing and inhibiting drugs.,Lamotrigine: pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429124/),h,24.1 and 35,55327,DB00555,Lamotrigine
,18433522,CL/F,"The population values of CL/F, V/F and KA were 1.16 L/h (0.042 L/h/kg), 40.2 L(1.46 L/kg) and 3.27/h for lamotrigine respectively in the final model.",[Population pharmacokinetics of lamotrigine in Chinese children with epilepsy]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18433522/),[l] / [h],1.16,61061,DB00555,Lamotrigine
,18433522,V/F,"The population values of CL/F, V/F and KA were 1.16 L/h (0.042 L/h/kg), 40.2 L(1.46 L/kg) and 3.27/h for lamotrigine respectively in the final model.",[Population pharmacokinetics of lamotrigine in Chinese children with epilepsy]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18433522/),l,40.2,61062,DB00555,Lamotrigine
,18433522,KA,"The population values of CL/F, V/F and KA were 1.16 L/h (0.042 L/h/kg), 40.2 L(1.46 L/kg) and 3.27/h for lamotrigine respectively in the final model.",[Population pharmacokinetics of lamotrigine in Chinese children with epilepsy]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18433522/),1/[h],3.27,61063,DB00555,Lamotrigine
,12576167,concentration at 1h (C(1h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],2.1,63306,DB00555,Lamotrigine
,12576167,concentration at 12h (C(12h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],0.8,63307,DB00555,Lamotrigine
,12576167,area under the curve from 0 to 12h (AUC(0-12h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],17.1,63308,DB00555,Lamotrigine
,12576167,half-life (t(1/2)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),h,8.1,63309,DB00555,Lamotrigine
,12576167,apparent oral clearance (CL/F),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),1/[mlmin],0.97,63310,DB00555,Lamotrigine
,12823574,AUCss,"The exposure, or area under the plasma LTG concentration-time curve within a dosing interval at steady state (AUCss), did not change in the presence of TPM, with mean AUCss values ranging at each TPM dose level between 66 and 81 mg x h/L with concomitant LTG/TPM therapy compared with 77 mgxh/L with LTG monotherapy.",Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12823574/),[h·mg] / [l],66 and 81,65036,DB00555,Lamotrigine
,12823574,AUCss,"The exposure, or area under the plasma LTG concentration-time curve within a dosing interval at steady state (AUCss), did not change in the presence of TPM, with mean AUCss values ranging at each TPM dose level between 66 and 81 mg x h/L with concomitant LTG/TPM therapy compared with 77 mgxh/L with LTG monotherapy.",Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12823574/),[h·mg] / [l],77,65037,DB00555,Lamotrigine
,12823574,oral clearance (CL/F),The mean (+/-SD) oral clearance (CL/F) of TPM (400 mg/day) was 2.6 +/- 1.1 L/h when given alone and 2.7 +/- 0.7 L/h when given with LTG.,Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12823574/),[l] / [h],2.6,65038,DB00555,Lamotrigine
,12823574,oral clearance (CL/F),The mean (+/-SD) oral clearance (CL/F) of TPM (400 mg/day) was 2.6 +/- 1.1 L/h when given alone and 2.7 +/- 0.7 L/h when given with LTG.,Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12823574/),[l] / [h],2.7,65039,DB00555,Lamotrigine
,25164097,polydispersity index,"The NLCs had a mean particle size of 151.6 ± 7.6 nm, polydispersity index of 0.249 ± 0.035, zeta potential of 11.75 ± 2.96 mV and EE of 96.64 ± 4.27%.",Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25164097/),,0.249,65104,DB00555,Lamotrigine
,25164097,zeta potential,"The NLCs had a mean particle size of 151.6 ± 7.6 nm, polydispersity index of 0.249 ± 0.035, zeta potential of 11.75 ± 2.96 mV and EE of 96.64 ± 4.27%.",Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25164097/),mv,11.75,65105,DB00555,Lamotrigine
,25164097,EE,"The NLCs had a mean particle size of 151.6 ± 7.6 nm, polydispersity index of 0.249 ± 0.035, zeta potential of 11.75 ± 2.96 mV and EE of 96.64 ± 4.27%.",Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25164097/),%,96.64,65106,DB00555,Lamotrigine
,25164097,flux,The drug release from NLCs followed Fickian diffusion with a flux value of 11.73 μgcm(-2)h(-1).,Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25164097/),1/[(μgcm)^2],11.73,65107,DB00555,Lamotrigine
,12091848,rate of partial seizures per,The rate of partial seizures per day decreased from 8.57 +/- 2.29 to 4.00 +/- 2.15 (P =.027) and infantile spasms from 8.71 +/- 2.15 to 3.61 +/- 2.762 (P =.028).,"Efficacy, tolerability, and kinetics of lamotrigine in infants. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12091848/),,8.57,65775,DB00555,Lamotrigine
,12091848,rate of partial seizures per,The rate of partial seizures per day decreased from 8.57 +/- 2.29 to 4.00 +/- 2.15 (P =.027) and infantile spasms from 8.71 +/- 2.15 to 3.61 +/- 2.762 (P =.028).,"Efficacy, tolerability, and kinetics of lamotrigine in infants. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12091848/),,4.00,65776,DB00555,Lamotrigine
,12091848,rate of partial seizures per,The rate of partial seizures per day decreased from 8.57 +/- 2.29 to 4.00 +/- 2.15 (P =.027) and infantile spasms from 8.71 +/- 2.15 to 3.61 +/- 2.762 (P =.028).,"Efficacy, tolerability, and kinetics of lamotrigine in infants. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12091848/),,8.71,65777,DB00555,Lamotrigine
,12091848,rate of partial seizures per,The rate of partial seizures per day decreased from 8.57 +/- 2.29 to 4.00 +/- 2.15 (P =.027) and infantile spasms from 8.71 +/- 2.15 to 3.61 +/- 2.762 (P =.028).,"Efficacy, tolerability, and kinetics of lamotrigine in infants. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12091848/),,3.61,65778,DB00555,Lamotrigine
,12091848,Apparent clearance,"Apparent clearance increased during the first year of life, with a break point at 2 months of age (mean, 0.119 +/- 0.021, 0.217 +/- 0.094 L/h per kilogram for infants <2 months and those 2 to 12 months old, respectively,P <.001).","Efficacy, tolerability, and kinetics of lamotrigine in infants. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12091848/),[l] / [h·kg],0.119,65779,DB00555,Lamotrigine
,12091848,Apparent clearance,"Apparent clearance increased during the first year of life, with a break point at 2 months of age (mean, 0.119 +/- 0.021, 0.217 +/- 0.094 L/h per kilogram for infants <2 months and those 2 to 12 months old, respectively,P <.001).","Efficacy, tolerability, and kinetics of lamotrigine in infants. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12091848/),[l] / [h·kg],0.217,65780,DB00555,Lamotrigine
,12091848,half-life,Twenty-four-hour concentration to time plots of three 3- to 4-week-old neonates showed a half-life of 23.44 +/- 3.57 hours.,"Efficacy, tolerability, and kinetics of lamotrigine in infants. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12091848/),h,23.44,65781,DB00555,Lamotrigine
,9332885,oral clearance,"Overall, CBZ oral clearance was unchanged following the introduction of LTG (5.58 +/- 1.60 vs. 5.81 +/- 1.74 1/h, P = 0.630).",Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332885/),[1] / [h],5.58,69746,DB00555,Lamotrigine
,9332885,oral clearance,"Overall, CBZ oral clearance was unchanged following the introduction of LTG (5.58 +/- 1.60 vs. 5.81 +/- 1.74 1/h, P = 0.630).",Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332885/),[1] / [h],5.81,69747,DB00555,Lamotrigine
,9332885,to,"Likewise, CBZE to CBZ serum concentration ratios were not significantly different (0.241 +/- 0.082 vs. 0.232 +/- 0.082, P = 0.782).",Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332885/),,0.241,69748,DB00555,Lamotrigine
,9332885,serum concentration ratios,"Likewise, CBZE to CBZ serum concentration ratios were not significantly different (0.241 +/- 0.082 vs. 0.232 +/- 0.082, P = 0.782).",Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332885/),,0.241,69749,DB00555,Lamotrigine
,9332885,serum concentration ratios,"Likewise, CBZE to CBZ serum concentration ratios were not significantly different (0.241 +/- 0.082 vs. 0.232 +/- 0.082, P = 0.782).",Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332885/),,0.232,69750,DB00555,Lamotrigine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.32,73970,DB00555,Lamotrigine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.34,73971,DB00555,Lamotrigine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.45,73972,DB00555,Lamotrigine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.46,73973,DB00555,Lamotrigine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.52,73974,DB00555,Lamotrigine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.53,73975,DB00555,Lamotrigine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.54,73976,DB00555,Lamotrigine
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.52,74496,DB00555,Lamotrigine
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.17,74497,DB00555,Lamotrigine
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.803,74498,DB00555,Lamotrigine
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.636,74499,DB00555,Lamotrigine
,15996535,flow rate,"Chromatographic separation was achieved on a C18 column with the mobile phase of acetonitrile-water containing 20 mM phosphate buffer (pH 7) (35/65, v/v), at a flow rate of 1 ml/min.",Determination of tadalafil in small volumes of plasma by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15996535/),[ml] / [min],1,76070,DB00555,Lamotrigine
,15996535,retention time,The retention time was about 4.5 min for lamotrigine and 15 min for tadalafil.,Determination of tadalafil in small volumes of plasma by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15996535/),min,4.5,76071,DB00555,Lamotrigine
,15996535,retention time,The retention time was about 4.5 min for lamotrigine and 15 min for tadalafil.,Determination of tadalafil in small volumes of plasma by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15996535/),min,15,76072,DB00555,Lamotrigine
greater,15996535,recovery,The recovery of tadalafil from plasma was greater than 77%.,Determination of tadalafil in small volumes of plasma by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15996535/),%,77,76073,DB00555,Lamotrigine
< or =,11145056,absolute recovery,The absolute recovery of the analyte in brain and plasma samples was < or = 90%.,"Determination of the enaminone DM5, an anti-epileptic agent, in mouse plasma and brain tissue by high-performance liquid chromatography with ultraviolet detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145056/),%,90,79604,DB00555,Lamotrigine
,8119045,bioavailability,The bioavailability of the oral formulation is about 98%.,Lamotrigine clinical pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),%,98,80086,DB00555,Lamotrigine
,8119045,plasma protein binding,The degree of plasma protein binding is 56%.,Lamotrigine clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),%,56,80087,DB00555,Lamotrigine
,8119045,half-lives,Mean half-lives of lamotrigine in healthy volunteers (single and multiple doses) as well as in epileptic patients receiving lamotrigine monotherapy range from 22.8 to 37.4 hours.,Lamotrigine clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),h,22.8 to 37.4,80088,DB00555,Lamotrigine
,8119045,half-life,"Enzyme-inducing antiepileptic drugs such as phenytoin, phenobarbital (phenobarbitone) or carbamazepine reduce the half-life of lamotrigine (to mean values of 13.5 to 15 hours), whereas valproic acid increases the half-life of the drug (to mean values of 48.3 to 59 hours).",Lamotrigine clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),h,13.5 to 15,80089,DB00555,Lamotrigine
,8119045,half-life,"Enzyme-inducing antiepileptic drugs such as phenytoin, phenobarbital (phenobarbitone) or carbamazepine reduce the half-life of lamotrigine (to mean values of 13.5 to 15 hours), whereas valproic acid increases the half-life of the drug (to mean values of 48.3 to 59 hours).",Lamotrigine clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),h,48.3 to 59,80090,DB00555,Lamotrigine
,25220641,Ka,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),1/[h],0.83,82170,DB00555,Lamotrigine
,25220641,Vd,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[l] / [kg],0.67,82171,DB00555,Lamotrigine
,25220641,CL,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[l] / [h·kg],0.035,82172,DB00555,Lamotrigine
,25220641,MP,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[mg] / [l],0.01,82173,DB00555,Lamotrigine
,25220641,MAE,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[mg] / [l],0.46,82174,DB00555,Lamotrigine
,25220641,MSE,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),,0.39,82175,DB00555,Lamotrigine
,30887226,Entrapment efficiency (EE%),Entrapment efficiency (EE%) of developed LTG-PLGA-NPs was found to be 84.87 ± 1.2% with drug loading of 10.21 ± 0.89%.,Nose-to-brain delivery of lamotrigine-loaded PLGA nanoparticles. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30887226/),%,84.87,83012,DB00555,Lamotrigine
,30887226,PDI,The particle size of developed nanoparticles was found to be 184.6 nm with PDI value of 0.082 and zeta potential of - 18.8 mV.,Nose-to-brain delivery of lamotrigine-loaded PLGA nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30887226/),,0.,83013,DB00555,Lamotrigine
,30887226,zeta potential,The particle size of developed nanoparticles was found to be 184.6 nm with PDI value of 0.082 and zeta potential of - 18.8 mV.,Nose-to-brain delivery of lamotrigine-loaded PLGA nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30887226/),m,18.8,83014,DB00555,Lamotrigine
,30887226,Cmax,"For 99mTc-LTG-PLGA-NPs via intra-nasal route, drug targeting efficiency (DTE%) was found to be 129.81% and drug target organ transport (DTP%) to be 22.81% in brain with Cmax of 3.82%/g within Tmax 1.5 h.",Nose-to-brain delivery of lamotrigine-loaded PLGA nanoparticles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30887226/),[%] / [g],3.82,83015,DB00555,Lamotrigine
,30887226,Tmax,"For 99mTc-LTG-PLGA-NPs via intra-nasal route, drug targeting efficiency (DTE%) was found to be 129.81% and drug target organ transport (DTP%) to be 22.81% in brain with Cmax of 3.82%/g within Tmax 1.5 h.",Nose-to-brain delivery of lamotrigine-loaded PLGA nanoparticles. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30887226/),h,1.5,83016,DB00555,Lamotrigine
,18076642,dose/plasma concentration ratio (D/C),"In group A, the mean dose/plasma concentration ratio (D/C) of LTG at baseline after pregnancy was 66.5 +/- 17.9 (+/- SD) L/day and approximately 250% higher in late pregnancy.",Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076642/),[l] / [d],66.5,83845,DB00555,Lamotrigine
,18076642,plasma concentration ratio (2-N-GLUC/LTG),The mean lamotrigine-2-N-glucuronide/lamotrigine plasma concentration ratio (2-N-GLUC/LTG) was 0.349 +/- 0.141 (+/- SD) at baseline and 147% higher in late pregnancy.,Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076642/),,0.349,83846,DB00555,Lamotrigine
,18043476,CL/F,The population estimate of CL/F from the base model was 5.14 L/h with interindividual variability of 50.20%.,Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043476/),[l] / [h],5.14,86360,DB00555,Lamotrigine
,32534880,trough,"Based on this model, we proposed dosage regimens to achieve trough lamotrigine concentrations within reference interval (2.5-15 mg/L).",Dosing Recommendations Based on Population Pharmacokinetics of Lamotrigine in Mexican Adult Patients With Epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32534880/),mg,2.5-15,88099,DB00555,Lamotrigine
,10840403,milk/maternal plasma concentration ratio,"The median milk/maternal plasma concentration ratio was 0.61 (range, 0.47-0.77) 2-3 weeks after delivery, and the nursed infants maintained LTG plasma concentrations of approximately 30% (median, range 23-50%) of the mother's plasma levels.","Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10840403/),,0.61,99464,DB00555,Lamotrigine
,10604819,metabolite-to-parent drug ratio,"The metabolite-to-parent drug ratio shifted from a median value of 2.8 in group A to 13 in group B, and up to 29 in patients receiving polytherapy with FBM (p < 0.001).",Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604819/),,2.8,99721,DB00555,Lamotrigine
,10604819,metabolite-to-parent drug ratio,"The metabolite-to-parent drug ratio shifted from a median value of 2.8 in group A to 13 in group B, and up to 29 in patients receiving polytherapy with FBM (p < 0.001).",Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604819/),,13,99722,DB00555,Lamotrigine
,10604819,metabolite-to-parent drug ratio,"The metabolite-to-parent drug ratio shifted from a median value of 2.8 in group A to 13 in group B, and up to 29 in patients receiving polytherapy with FBM (p < 0.001).",Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604819/),,29,99723,DB00555,Lamotrigine
,12076842,Cl(o),"In a subset analysis of completers, LTG Cl(o) determined prior to withdrawal of the inducers was significantly greater in patients (n=28) on LTG+PHT (160% increase) than in those (n=48) receiving LTG+CBZ (62% increase): 1.77+/-0.77 vs. 1.06+/-0.41 ml/min/kg, respectively, p=0.017.",Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine or phenytoin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12076842/),[ml] / [kg·min],1.77,103868,DB00555,Lamotrigine
,12076842,Cl(o),"In a subset analysis of completers, LTG Cl(o) determined prior to withdrawal of the inducers was significantly greater in patients (n=28) on LTG+PHT (160% increase) than in those (n=48) receiving LTG+CBZ (62% increase): 1.77+/-0.77 vs. 1.06+/-0.41 ml/min/kg, respectively, p=0.017.",Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine or phenytoin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12076842/),[ml] / [kg·min],1.06,103869,DB00555,Lamotrigine
,27392922,half-life of elimination,"Its average half-life of elimination is of the order of 22 h, but it is reduced approximately at 14h if it is associated with enzymatic inductors and increased at 70h if lamotrigine is administered with sodium valproate.",Suivi thérapeutique pharmacologique de la lamotrigine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27392922/),h,22,104483,DB00555,Lamotrigine
over,10612356,elimination half-lives,"The route of elimination differs to an important extent from one compound to another, and elimination half-lives range from over 30 h for zonisamide to 5-7 h for gabapentin.",The clinical pharmacokinetics of the new antiepileptic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10612356/),h,30,106800,DB00555,Lamotrigine
,10612356,elimination half-lives,"The route of elimination differs to an important extent from one compound to another, and elimination half-lives range from over 30 h for zonisamide to 5-7 h for gabapentin.",The clinical pharmacokinetics of the new antiepileptic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10612356/),h,5-7,106801,DB00555,Lamotrigine
,24883336,CL/F,The baseline LTG CL/F was 2.16 L/h with a between-subject variability of 40.6%.,MODEL-BASED LAMOTRIGINE CLEARANCE CHANGES DURING PREGNANCY: CLINICAL IMPLICATION. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24883336/),[l] / [h],2.16,108072,DB00555,Lamotrigine
,24883336,CL/F,The gestational age-associated increase in CL/F displayed a ten-fold higher rate in 77% of the women (0.118 L/h/week) compared to 23% (0.0115 L/h/week).,MODEL-BASED LAMOTRIGINE CLEARANCE CHANGES DURING PREGNANCY: CLINICAL IMPLICATION. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24883336/),[l] / [h·week],0.118,108073,DB00555,Lamotrigine
,24883336,CL/F,The gestational age-associated increase in CL/F displayed a ten-fold higher rate in 77% of the women (0.118 L/h/week) compared to 23% (0.0115 L/h/week).,MODEL-BASED LAMOTRIGINE CLEARANCE CHANGES DURING PREGNANCY: CLINICAL IMPLICATION. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24883336/),[l] / [h·week],0.0115,108074,DB00555,Lamotrigine
,24883336,half-life,The increased CL/F at delivery declined to baseline values with a half-life of 0.55 weeks.,MODEL-BASED LAMOTRIGINE CLEARANCE CHANGES DURING PREGNANCY: CLINICAL IMPLICATION. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24883336/),weeks,0.55,108075,DB00555,Lamotrigine
,24883336,CL/F,"The majority of women had a substantial increase in CL/F from 2.16 to 6.88 L/h by the end of pregnancy, whereas 23% of women had a minimal increase.",MODEL-BASED LAMOTRIGINE CLEARANCE CHANGES DURING PREGNANCY: CLINICAL IMPLICATION. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24883336/),[l] / [h],2.16,108076,DB00555,Lamotrigine
,24883336,CL/F,"The majority of women had a substantial increase in CL/F from 2.16 to 6.88 L/h by the end of pregnancy, whereas 23% of women had a minimal increase.",MODEL-BASED LAMOTRIGINE CLEARANCE CHANGES DURING PREGNANCY: CLINICAL IMPLICATION. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24883336/),[l] / [h],6.88,108077,DB00555,Lamotrigine
,3504397,plasma elimination half-life (T1/2),Patients taking liver enzyme inducing antiepileptic drugs showed a mean lamotrigine plasma elimination half-life (T1/2) of 14 h (+/- 7) (T1/2 of normal volunteers = 24 h) and those taking sodium valproate and an inducing AED showed a mean lamotrigine T1/2 of 30 h (+/- 10).,Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3504397/),h,14,108309,DB00555,Lamotrigine
,3504397,T1/2,Patients taking liver enzyme inducing antiepileptic drugs showed a mean lamotrigine plasma elimination half-life (T1/2) of 14 h (+/- 7) (T1/2 of normal volunteers = 24 h) and those taking sodium valproate and an inducing AED showed a mean lamotrigine T1/2 of 30 h (+/- 10).,Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3504397/),h,24,108310,DB00555,Lamotrigine
,3504397,T1/2,Patients taking liver enzyme inducing antiepileptic drugs showed a mean lamotrigine plasma elimination half-life (T1/2) of 14 h (+/- 7) (T1/2 of normal volunteers = 24 h) and those taking sodium valproate and an inducing AED showed a mean lamotrigine T1/2 of 30 h (+/- 10).,Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3504397/),h,30,108311,DB00555,Lamotrigine
,22660444,Clearance (CL),Clearance (CL) was estimated to be 2.27 L/h with inter-individual variability (IIV) of 29 CV%.,Population pharmacokinetics of lamotrigine in Indian epileptic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22660444/),[l] / [h],2.27,111841,DB00555,Lamotrigine
,22660444,Volume of distribution (V),Volume of distribution (V) was estimated to be 53.6 L (31 CV% IIV).,Population pharmacokinetics of lamotrigine in Indian epileptic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22660444/),l,53.6,111842,DB00555,Lamotrigine
,23891703,Volume of distribution,Volume of distribution of TPM was estimated at 0.575 l/kg.,Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891703/),[l] / [kg],0.575,116785,DB00555,Lamotrigine
,23891703,CL/F,"Mean TPM CL/F during CBZ co-therapy was 2.46 l/h, which is higher for 60.8% than in patients not co-treated with CBZ.",Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891703/),[l] / [h],2.46,116786,DB00555,Lamotrigine
,12681002,volume of distribution (Vd,"LTG was given as a single oral dose calculated based on the population expected volume of distribution (Vd, 1.0 L/kg) and target blood level on admission.",Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring units. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12681002/),[l] / [kg],1.0,119030,DB00555,Lamotrigine
,12681002,Tmax,"The mean estimated pharmacokinetic parameters are as follows: Tmax, 3.1 +/- 2.1 h; Cmax, 8.2 +/- 6.5 mg/L; Vd, 1.1 +/- 1.0 L/kg; clearance, 0.08 +/- 0.08 mg/L/h; half-life, 22 +/- 30 h.",Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring units. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12681002/),h,3.1,119031,DB00555,Lamotrigine
,12681002,Cmax,"The mean estimated pharmacokinetic parameters are as follows: Tmax, 3.1 +/- 2.1 h; Cmax, 8.2 +/- 6.5 mg/L; Vd, 1.1 +/- 1.0 L/kg; clearance, 0.08 +/- 0.08 mg/L/h; half-life, 22 +/- 30 h.",Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring units. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12681002/),[mg] / [l],8.2,119032,DB00555,Lamotrigine
,12681002,Vd,"The mean estimated pharmacokinetic parameters are as follows: Tmax, 3.1 +/- 2.1 h; Cmax, 8.2 +/- 6.5 mg/L; Vd, 1.1 +/- 1.0 L/kg; clearance, 0.08 +/- 0.08 mg/L/h; half-life, 22 +/- 30 h.",Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring units. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12681002/),[l] / [kg],1.1,119033,DB00555,Lamotrigine
,12681002,clearance,"The mean estimated pharmacokinetic parameters are as follows: Tmax, 3.1 +/- 2.1 h; Cmax, 8.2 +/- 6.5 mg/L; Vd, 1.1 +/- 1.0 L/kg; clearance, 0.08 +/- 0.08 mg/L/h; half-life, 22 +/- 30 h.",Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring units. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12681002/),[mg] / [h·l],0.08,119034,DB00555,Lamotrigine
,12681002,half-life,"The mean estimated pharmacokinetic parameters are as follows: Tmax, 3.1 +/- 2.1 h; Cmax, 8.2 +/- 6.5 mg/L; Vd, 1.1 +/- 1.0 L/kg; clearance, 0.08 +/- 0.08 mg/L/h; half-life, 22 +/- 30 h.",Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring units. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12681002/),h,22,119035,DB00555,Lamotrigine
,22426846,dose corrected concentration,"The dose corrected concentration of lamotrigine in patients receiving lamotrigine in combination with sertraline was 60.4 μmol/L × 1,000/mg/day (SD: 31.1) (N = 7) compared to 51.1 μmol/L × 1 000/mg/day (SD: 27.6) (N = 44) in patients using lamotrigine without sertraline (p = 0.42).",Lack of interaction between sertraline and lamotrigine in psychiatric patients: a retrospective study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22426846/),"[μM] / [1,000·d·l·mg]",60.4,120941,DB00555,Lamotrigine
,22426846,dose corrected concentration,"The dose corrected concentration of lamotrigine in patients receiving lamotrigine in combination with sertraline was 60.4 μmol/L × 1,000/mg/day (SD: 31.1) (N = 7) compared to 51.1 μmol/L × 1 000/mg/day (SD: 27.6) (N = 44) in patients using lamotrigine without sertraline (p = 0.42).",Lack of interaction between sertraline and lamotrigine in psychiatric patients: a retrospective study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22426846/),[μM] / [000·1·d·l·mg],51.1,120942,DB00555,Lamotrigine
,12698305,half-life (t(1/2)),RGB was rapidly absorbed and eliminated with a mean half-life (t(1/2)) of 6.3+/-1.1 h and an apparent clearance (CL/F) of 0.69+/-1.4 l/h/kg.,Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698305/),h,6.3,123229,DB00555,Lamotrigine
,12698305,apparent clearance (CL/F),RGB was rapidly absorbed and eliminated with a mean half-life (t(1/2)) of 6.3+/-1.1 h and an apparent clearance (CL/F) of 0.69+/-1.4 l/h/kg.,Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698305/),[l] / [h·kg],0.69,123230,DB00555,Lamotrigine
,12698305,t(1/2),"LTG was moderately rapidly absorbed, eliminated with a mean t(1/2) of 37+/-10.4 h and a CL/F of 0.028+/-0.007 l/h/kg.",Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698305/),h,37,123231,DB00555,Lamotrigine
,12698305,CL/F,"LTG was moderately rapidly absorbed, eliminated with a mean t(1/2) of 37+/-10.4 h and a CL/F of 0.028+/-0.007 l/h/kg.",Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698305/),[l] / [h·kg],0.028,123232,DB00555,Lamotrigine
,3677542,elimination half-life (t1/2),In a second study 10 subjects received 120 mg lamotrigine and the mean (+/- SD) of the elimination half-life (t1/2) was 24.1 +/- 5.7 hours and of volume of distribution/bioavailability 1.2 +/- 0.12 L/kg.,"Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677542/),h,24.1,124526,DB00555,Lamotrigine
,3677542,volume of distribution/bioavailability,In a second study 10 subjects received 120 mg lamotrigine and the mean (+/- SD) of the elimination half-life (t1/2) was 24.1 +/- 5.7 hours and of volume of distribution/bioavailability 1.2 +/- 0.12 L/kg.,"Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677542/),[l] / [kg],1.2,124527,DB00555,Lamotrigine
,3677542,Total urinary recovery of drug,Total urinary recovery of drug over 144 hours was 70.5% of the oral dose.,"Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677542/),%,70.5,124528,DB00555,Lamotrigine
,3677542,overall plasma elimination t1/2,The overall plasma elimination t1/2 calculated from data during the 7 days was 25.5 +/- 10.2 hours.,"Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677542/),h,25.5,124529,DB00555,Lamotrigine
,21838791,CL,Median LTG CL of older adults taking LTG in monotherapy was approximately 22% lower compared to younger adults (28.8 vs. 36.5 ml/h/kg; p < 0.001).,"The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21838791/),[ml] / [h·kg],28.8,124660,DB00555,Lamotrigine
,21838791,CL,Median LTG CL of older adults taking LTG in monotherapy was approximately 22% lower compared to younger adults (28.8 vs. 36.5 ml/h/kg; p < 0.001).,"The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21838791/),[ml] / [h·kg],36.5,124661,DB00555,Lamotrigine
,21838791,Intolerability,Intolerability to LTG was higher in older (34.8%) versus younger adults (24.2%; p = 0.005).,"The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21838791/),%,34.8,124662,DB00555,Lamotrigine
,21838791,Intolerability,Intolerability to LTG was higher in older (34.8%) versus younger adults (24.2%; p = 0.005).,"The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21838791/),%,24.2,124663,DB00555,Lamotrigine
,18611447,elimination half-life (t(1/2)),The results revealed fluctuations exceeding those expected from its elimination half-life (t(1/2)) of 22h as reported in the literature.,Diurnal lamotrigine plasma level fluctuations: clinical significance and indication of shorter half-life with chronic administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611447/),h,22,124928,DB00555,Lamotrigine
,18611447,C(min)/C(max) ratios,Patients on twice-daily regimens without pharmacokinetic interactions exhibited C(min)/C(max) ratios between 0.62 and 0.69.,Diurnal lamotrigine plasma level fluctuations: clinical significance and indication of shorter half-life with chronic administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611447/),,0.62,124929,DB00555,Lamotrigine
,18611447,C(min)/C(max) ratios,Patients on twice-daily regimens without pharmacokinetic interactions exhibited C(min)/C(max) ratios between 0.62 and 0.69.,Diurnal lamotrigine plasma level fluctuations: clinical significance and indication of shorter half-life with chronic administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611447/),,0.,124930,DB00555,Lamotrigine
,33857625,apparent LTG clearance (CL/F),"In the refined PopPK model, the population mean of apparent LTG clearance (CL/F) in pregnant WWE was estimated to be 2.82 L/h, with an inter-individual variability of 23.6%.",Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33857625/),[l] / [h],2.82,129035,DB00555,Lamotrigine
,33857625,CL/F,"Up to the 3rd trimester, the concentration accumulation effect of E2 increased LTG-CL/F by 5.109 L/h from baseline levels.",Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33857625/),l,5,129036,DB00555,Lamotrigine
,33857625,peak value,"Contrary to effect of E2, E3 as the main circulating estrogen in pregnancy with a peak value of 34.41 ng/mL is 1000-fold higher than that in non-pregnancy reduced LTG-CL/F by 1.413 L/h.",Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33857625/),[ng] / [ml],34.41,129037,DB00555,Lamotrigine
,33857625,CL/F,"Contrary to effect of E2, E3 as the main circulating estrogen in pregnancy with a peak value of 34.41 ng/mL is 1000-fold higher than that in non-pregnancy reduced LTG-CL/F by 1.413 L/h.",Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33857625/),l,1.413,129038,DB00555,Lamotrigine
,1773780,peak plasma concentrations,"In an open dose-escalating study, LTG 240 mg produced peak plasma concentrations of around 3 micrograms/mg with no significant adverse events.",Clinical pharmacology of lamotrigine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773780/),[μg] / [mg],3,130119,DB00555,Lamotrigine
,1773780,half-life,"Subsequent pharmacokinetic studies revealed complete oral absorption, first-order kinetics with a mean half-life of approximately 1 day, and elimination mainly as a glucuronide in the urine.",Clinical pharmacology of lamotrigine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773780/),d,1,130120,DB00555,Lamotrigine
,26865186,half-life,"The half-life of retigabine in plasma was 2.5 h, with appreciable concentrations reached in the brain within 1 h of administration.",Profile of retigabine-induced neuronal apoptosis in the developing rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865186/),h,2.5,135025,DB00555,Lamotrigine
,2804994,clearances (dose/AUC),"On these days, the mean (+/- SD) LTG clearances (dose/AUC) were 0.0436 +/- 0.0171, 0.0468 +/- 0.0093, and 0.0575 +/- 0.0160 L/h/kg, respectively.","Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804994/),[l] / [h·kg],0.0436,135251,DB00555,Lamotrigine
,2804994,clearances (dose/AUC),"On these days, the mean (+/- SD) LTG clearances (dose/AUC) were 0.0436 +/- 0.0171, 0.0468 +/- 0.0093, and 0.0575 +/- 0.0160 L/h/kg, respectively.","Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804994/),[l] / [h·kg],0.0468,135252,DB00555,Lamotrigine
,2804994,clearances (dose/AUC),"On these days, the mean (+/- SD) LTG clearances (dose/AUC) were 0.0436 +/- 0.0171, 0.0468 +/- 0.0093, and 0.0575 +/- 0.0160 L/h/kg, respectively.","Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804994/),[l] / [h·kg],0.0575,135253,DB00555,Lamotrigine
,2804994,trough levels,"In conclusion, when given for long periods of time (9.5 months to 2 years), LTG was well tolerated in doses up to 400 mg/day and mean trough levels of 3.0 +/- 0.6 microgram/ml; LTG has a favorable pharmacokinetic profile and appears to exhibit first-order linear kinetics during long-term chronic dosing; LTG shows preliminary evidence of efficacy during long-term administration; and to date, our patients represent the longest reported experience of continuous and closely monitored LTG therapy in the literature.","Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804994/),[μg] / [ml],3.0,135254,DB00555,Lamotrigine
,15652736,trough serum concentrations,"Among the 67 patients with at least one lamotrigine trough serum concentration after initiation of therapy (pharmacokinetic population), mean trough serum concentrations at the end of the lamotrigine escalation phase at a lamotrigine daily dose of 200 mg (7.9 microg/mL, SD = 3.3) did not differ significantly from values during the valproate withdrawal phase (8.7 microg/mL, SD = 3.5) and the lamotrigine monotherapy phase at a lamotrigine dose of 500 mg daily (7.2 microg/mL, SD = 3.3).",A dosing algorithm for converting from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652736/),[μg] / [ml],7.9,137398,DB00555,Lamotrigine
,15652736,trough serum concentrations,"Among the 67 patients with at least one lamotrigine trough serum concentration after initiation of therapy (pharmacokinetic population), mean trough serum concentrations at the end of the lamotrigine escalation phase at a lamotrigine daily dose of 200 mg (7.9 microg/mL, SD = 3.3) did not differ significantly from values during the valproate withdrawal phase (8.7 microg/mL, SD = 3.5) and the lamotrigine monotherapy phase at a lamotrigine dose of 500 mg daily (7.2 microg/mL, SD = 3.3).",A dosing algorithm for converting from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652736/),[μg] / [ml],8.7,137399,DB00555,Lamotrigine
,15652736,trough serum concentrations,"Among the 67 patients with at least one lamotrigine trough serum concentration after initiation of therapy (pharmacokinetic population), mean trough serum concentrations at the end of the lamotrigine escalation phase at a lamotrigine daily dose of 200 mg (7.9 microg/mL, SD = 3.3) did not differ significantly from values during the valproate withdrawal phase (8.7 microg/mL, SD = 3.5) and the lamotrigine monotherapy phase at a lamotrigine dose of 500 mg daily (7.2 microg/mL, SD = 3.3).",A dosing algorithm for converting from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652736/),[μg] / [ml],7.2,137400,DB00555,Lamotrigine
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.045-0.070,137436,DB00555,Lamotrigine
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.028,137437,DB00555,Lamotrigine
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.014,137438,DB00555,Lamotrigine
,2225696,Area under the plasma concentration-time curve for lamotrigine [AUC(O-infinity)],"Area under the plasma concentration-time curve for lamotrigine [AUC(O-infinity)] and lamotrigine half-life were statistically decreased by 20% (229.0 +/- 62.5 micrograms.hr/ml versus 191.2 +/- 42.1 micrograms.hr/ml, p less than 0.01) and 15% (35.7 +/- 9.3 hours versus 30.2 +/- 7.3 hours, p less than 0.01), respectively, when concurrently administered with acetaminophen.",Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225696/),[h·μg] / [ml],229.0,144171,DB00555,Lamotrigine
,2225696,Area under the plasma concentration-time curve for lamotrigine [AUC(O-infinity)],"Area under the plasma concentration-time curve for lamotrigine [AUC(O-infinity)] and lamotrigine half-life were statistically decreased by 20% (229.0 +/- 62.5 micrograms.hr/ml versus 191.2 +/- 42.1 micrograms.hr/ml, p less than 0.01) and 15% (35.7 +/- 9.3 hours versus 30.2 +/- 7.3 hours, p less than 0.01), respectively, when concurrently administered with acetaminophen.",Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225696/),[h·μg] / [ml],191.2,144172,DB00555,Lamotrigine
,2225696,Area under the plasma concentration-time curve for lamotrigine [AUC(O-infinity)],"Area under the plasma concentration-time curve for lamotrigine [AUC(O-infinity)] and lamotrigine half-life were statistically decreased by 20% (229.0 +/- 62.5 micrograms.hr/ml versus 191.2 +/- 42.1 micrograms.hr/ml, p less than 0.01) and 15% (35.7 +/- 9.3 hours versus 30.2 +/- 7.3 hours, p less than 0.01), respectively, when concurrently administered with acetaminophen.",Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225696/),h,35.7,144173,DB00555,Lamotrigine
,2225696,half-life,"Area under the plasma concentration-time curve for lamotrigine [AUC(O-infinity)] and lamotrigine half-life were statistically decreased by 20% (229.0 +/- 62.5 micrograms.hr/ml versus 191.2 +/- 42.1 micrograms.hr/ml, p less than 0.01) and 15% (35.7 +/- 9.3 hours versus 30.2 +/- 7.3 hours, p less than 0.01), respectively, when concurrently administered with acetaminophen.",Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225696/),[h·μg] / [ml],191.2,144174,DB00555,Lamotrigine
,2225696,half-life,"Area under the plasma concentration-time curve for lamotrigine [AUC(O-infinity)] and lamotrigine half-life were statistically decreased by 20% (229.0 +/- 62.5 micrograms.hr/ml versus 191.2 +/- 42.1 micrograms.hr/ml, p less than 0.01) and 15% (35.7 +/- 9.3 hours versus 30.2 +/- 7.3 hours, p less than 0.01), respectively, when concurrently administered with acetaminophen.",Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225696/),h,35.7,144175,DB00555,Lamotrigine
,2225696,half-life,"Area under the plasma concentration-time curve for lamotrigine [AUC(O-infinity)] and lamotrigine half-life were statistically decreased by 20% (229.0 +/- 62.5 micrograms.hr/ml versus 191.2 +/- 42.1 micrograms.hr/ml, p less than 0.01) and 15% (35.7 +/- 9.3 hours versus 30.2 +/- 7.3 hours, p less than 0.01), respectively, when concurrently administered with acetaminophen.",Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225696/),h,30.2,144176,DB00555,Lamotrigine
,27096250,absorption rate,"With a base model absorption rate (interindividual variability) was estimated at 1.96 h(-1) (72.8%), oral clearance at 2.32 l h(-1) (41.4%) and distribution volume at 77.6 l (30.2%).",Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27096250/),1/[h],1.96,144962,DB00555,Lamotrigine
,27096250,oral clearance,"With a base model absorption rate (interindividual variability) was estimated at 1.96 h(-1) (72.8%), oral clearance at 2.32 l h(-1) (41.4%) and distribution volume at 77.6 l (30.2%).",Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27096250/),[l] / [h],2.32,144963,DB00555,Lamotrigine
,27096250,distribution volume,"With a base model absorption rate (interindividual variability) was estimated at 1.96 h(-1) (72.8%), oral clearance at 2.32 l h(-1) (41.4%) and distribution volume at 77.6 l (30.2%).",Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27096250/),l,77.6,144964,DB00555,Lamotrigine
,9558136,detection limit,The method had a LTG detection limit of 0.02 microg/ml in plasma and 0.03 microg/ml in urine.,Determination of lamotrigine in biologic materials by a simple and rapid liquid chromatographic method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9558136/),[μg] / [ml],0.02,145297,DB00555,Lamotrigine
,9558136,detection limit,The method had a LTG detection limit of 0.02 microg/ml in plasma and 0.03 microg/ml in urine.,Determination of lamotrigine in biologic materials by a simple and rapid liquid chromatographic method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9558136/),[μg] / [ml],0.03,145298,DB00555,Lamotrigine
,9558136,recovery,"The recovery of LTG added to plasma, urine, and brain homogenate ranged from 98% to 100%.",Determination of lamotrigine in biologic materials by a simple and rapid liquid chromatographic method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9558136/),%,98,145299,DB00555,Lamotrigine
,9558136,recovery,"The recovery of LTG added to plasma, urine, and brain homogenate ranged from 98% to 100%.",Determination of lamotrigine in biologic materials by a simple and rapid liquid chromatographic method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9558136/),%,100,145300,DB00555,Lamotrigine
,10954343,clearance over bioavailability (CL/F),"The values of the pharmacokinetic parameters of lamotrigine were: clearance over bioavailability (CL/F) 2.60+/-0.40 l/h, renal clearance (CLR) 0.10+/-0.03 l/h, terminal half-life (t1/2) 23.8+/-2.1 h, mean peak serum concentration (Cmax) 0.29+/-0.02 microg/l, time to reach Cmax (tmax) 1.6+/-0.28 h, and total area under the serum concentration-time curve (AUC0-infinity) 703.99+/-82.31 microg/ ml/min (mean +/- SEM).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),[l] / [h],2.60,146191,DB00555,Lamotrigine
,10954343,renal clearance (CLR),"The values of the pharmacokinetic parameters of lamotrigine were: clearance over bioavailability (CL/F) 2.60+/-0.40 l/h, renal clearance (CLR) 0.10+/-0.03 l/h, terminal half-life (t1/2) 23.8+/-2.1 h, mean peak serum concentration (Cmax) 0.29+/-0.02 microg/l, time to reach Cmax (tmax) 1.6+/-0.28 h, and total area under the serum concentration-time curve (AUC0-infinity) 703.99+/-82.31 microg/ ml/min (mean +/- SEM).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),[l] / [h],0.10,146192,DB00555,Lamotrigine
,10954343,terminal half-life (t1/2),"The values of the pharmacokinetic parameters of lamotrigine were: clearance over bioavailability (CL/F) 2.60+/-0.40 l/h, renal clearance (CLR) 0.10+/-0.03 l/h, terminal half-life (t1/2) 23.8+/-2.1 h, mean peak serum concentration (Cmax) 0.29+/-0.02 microg/l, time to reach Cmax (tmax) 1.6+/-0.28 h, and total area under the serum concentration-time curve (AUC0-infinity) 703.99+/-82.31 microg/ ml/min (mean +/- SEM).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),h,23.8,146193,DB00555,Lamotrigine
,10954343,peak serum concentration (Cmax),"The values of the pharmacokinetic parameters of lamotrigine were: clearance over bioavailability (CL/F) 2.60+/-0.40 l/h, renal clearance (CLR) 0.10+/-0.03 l/h, terminal half-life (t1/2) 23.8+/-2.1 h, mean peak serum concentration (Cmax) 0.29+/-0.02 microg/l, time to reach Cmax (tmax) 1.6+/-0.28 h, and total area under the serum concentration-time curve (AUC0-infinity) 703.99+/-82.31 microg/ ml/min (mean +/- SEM).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),[μg] / [l],0.29,146194,DB00555,Lamotrigine
,10954343,time to reach Cmax (tmax),"The values of the pharmacokinetic parameters of lamotrigine were: clearance over bioavailability (CL/F) 2.60+/-0.40 l/h, renal clearance (CLR) 0.10+/-0.03 l/h, terminal half-life (t1/2) 23.8+/-2.1 h, mean peak serum concentration (Cmax) 0.29+/-0.02 microg/l, time to reach Cmax (tmax) 1.6+/-0.28 h, and total area under the serum concentration-time curve (AUC0-infinity) 703.99+/-82.31 microg/ ml/min (mean +/- SEM).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),h,1.6,146195,DB00555,Lamotrigine
,10954343,total area under the serum concentration-time curve (AUC0-infinity),"The values of the pharmacokinetic parameters of lamotrigine were: clearance over bioavailability (CL/F) 2.60+/-0.40 l/h, renal clearance (CLR) 0.10+/-0.03 l/h, terminal half-life (t1/2) 23.8+/-2.1 h, mean peak serum concentration (Cmax) 0.29+/-0.02 microg/l, time to reach Cmax (tmax) 1.6+/-0.28 h, and total area under the serum concentration-time curve (AUC0-infinity) 703.99+/-82.31 microg/ ml/min (mean +/- SEM).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),[μg] / [min·ml],703.99,146196,DB00555,Lamotrigine
,10954343,amount,The amount of lamotrigine excreted as glucuronide was 8.90+/-0.77 mg.,Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),mg,8.90,146197,DB00555,Lamotrigine
,10954343,excreted,The amount of lamotrigine excreted as glucuronide was 8.90+/-0.77 mg.,Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),mg,8.90,146198,DB00555,Lamotrigine
,10954343,CL/F,"Rifampicin significantly increased CL/F (5.13+/-1.05 l/h) and the amount of lamotrigine excreted as glucuronide (12.12+/-0.94 mg), whereas both t1/2 (14.1+/-1.7 h) and AUC(0-infinity) (396.24+/-60.18 microg/ml/min) were decreased (P<0.05).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),[l] / [h],5.13,146199,DB00555,Lamotrigine
,10954343,t1/2,"Rifampicin significantly increased CL/F (5.13+/-1.05 l/h) and the amount of lamotrigine excreted as glucuronide (12.12+/-0.94 mg), whereas both t1/2 (14.1+/-1.7 h) and AUC(0-infinity) (396.24+/-60.18 microg/ml/min) were decreased (P<0.05).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),h,14.1,146200,DB00555,Lamotrigine
,10954343,AUC(0-infinity),"Rifampicin significantly increased CL/F (5.13+/-1.05 l/h) and the amount of lamotrigine excreted as glucuronide (12.12+/-0.94 mg), whereas both t1/2 (14.1+/-1.7 h) and AUC(0-infinity) (396.24+/-60.18 microg/ml/min) were decreased (P<0.05).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),[μg] / [min·ml],396.24,146201,DB00555,Lamotrigine
,20205994,half-life of elimination,"Its average half-life of elimination is of the order of 22 h, but it is reduced approximately at 14 h if it is associated with enzymatic inductors and increased at 70 h if lamotrigine is administered with sodium valproate.",[Therapeutic drug monitoring of lamotrigine]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20205994/),h,22,152243,DB00555,Lamotrigine
,19209284,half-life,"Furthermore, though the average half-life in monotherapy is about 24 hours, there is a large inter-individual variation that may, including the extremes, approach a range of 10-fold.",Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19209284/),h,24,154774,DB00555,Lamotrigine
,16005693,Rf,Densitometric analysis was carried out at 312 nm with lamotrigine being detected at Rf of 0.54.,High-performance thin-layer chromatographic determination of lamotrigine in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005693/),,0.54,156185,DB00555,Lamotrigine
,16005693,limit of detection,"The limit of detection and limit of quantification were found to be 6.4 and 10.2 ng, respectively.",High-performance thin-layer chromatographic determination of lamotrigine in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005693/),ng,6.4,156186,DB00555,Lamotrigine
,16005693,limit of quantification,"The limit of detection and limit of quantification were found to be 6.4 and 10.2 ng, respectively.",High-performance thin-layer chromatographic determination of lamotrigine in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005693/),ng,10.2,156187,DB00555,Lamotrigine
,11097146,elimination half-life,The mean (+/- SEM) elimination half-life of CBZ was 33.0+/-1.8 h after pretreatment with placebo and 30.1+/-2.0 h after a one-week-pretreatment with LTG (NS).,Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097146/),h,33.0,157177,DB00555,Lamotrigine
,11097146,elimination half-life,The mean (+/- SEM) elimination half-life of CBZ was 33.0+/-1.8 h after pretreatment with placebo and 30.1+/-2.0 h after a one-week-pretreatment with LTG (NS).,Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097146/),h,30.1,157178,DB00555,Lamotrigine
,11097146,area under the serum concentration curve to infinity (AUC),The area under the serum concentration curve to infinity (AUC) of CBZ was 638+/-45 micromol/l after placebo and 624+/-53 micromol/l after LTG (NS).,Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097146/),[μM] / [l],638,157179,DB00555,Lamotrigine
,11097146,area under the serum concentration curve to infinity (AUC),The area under the serum concentration curve to infinity (AUC) of CBZ was 638+/-45 micromol/l after placebo and 624+/-53 micromol/l after LTG (NS).,Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097146/),[μM] / [l],624,157180,DB00555,Lamotrigine
,11097146,peak serum concentration,"Changes in the peak serum concentration, from 9.0+/-0.3 micromol/l to 9.2+/-0.4 micromol/l (LTG), and in the time to peak serum concentration, from 9.3+/-1.1 h to 9.1+/-1.2 h (LTG), were also not significant.",Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097146/),[μM] / [l],9.0,157181,DB00555,Lamotrigine
,11097146,peak serum concentration,"Changes in the peak serum concentration, from 9.0+/-0.3 micromol/l to 9.2+/-0.4 micromol/l (LTG), and in the time to peak serum concentration, from 9.3+/-1.1 h to 9.1+/-1.2 h (LTG), were also not significant.",Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097146/),[μM] / [l],9.2,157182,DB00555,Lamotrigine
,11097146,time to peak serum concentration,"Changes in the peak serum concentration, from 9.0+/-0.3 micromol/l to 9.2+/-0.4 micromol/l (LTG), and in the time to peak serum concentration, from 9.3+/-1.1 h to 9.1+/-1.2 h (LTG), were also not significant.",Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097146/),h,9.3,157183,DB00555,Lamotrigine
,11097146,time to peak serum concentration,"Changes in the peak serum concentration, from 9.0+/-0.3 micromol/l to 9.2+/-0.4 micromol/l (LTG), and in the time to peak serum concentration, from 9.3+/-1.1 h to 9.1+/-1.2 h (LTG), were also not significant.",Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097146/),h,9.1,157184,DB00555,Lamotrigine
,30511473,clearance,The pharmacokinetic modelling with a mixture routine identified two subpopulations: 88% had a mean clearance of 1.99 l h-1 ; 12% had a mean clearance of 0.64 l h-1 .,Adjustment of the area under the concentration curve by terminal rate constant for bioequivalence assessment in a parallel-group study of lamotrigine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30511473/),[l] / [h],1.99,157242,DB00555,Lamotrigine
,30511473,clearance,The pharmacokinetic modelling with a mixture routine identified two subpopulations: 88% had a mean clearance of 1.99 l h-1 ; 12% had a mean clearance of 0.64 l h-1 .,Adjustment of the area under the concentration curve by terminal rate constant for bioequivalence assessment in a parallel-group study of lamotrigine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30511473/),[l] / [h],0.64,157243,DB00555,Lamotrigine
,10807660,half-life,"The serum pharmacokinetics were biphasic with an initial distribution phase, (half-life approximately 3 h), and then a prolonged elimination phase of over 30 h.","Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10807660/),h,3,157810,DB00555,Lamotrigine
,10807660,penetration half-time into CSF,"Using direct sampling of CSF with concomitant serum sampling, the calculated penetration half-time into CSF was 0.42+/-0.15 h.","Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10807660/),h,0.42,157811,DB00555,Lamotrigine
,10807660,CSF to total serum concentration ratio,"At equilibrium, the CSF to total serum concentration ratio (0.61+/-0.02) was greater than the free to total serum concentration (0.39+/-0.01).","Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10807660/),,0.61,157812,DB00555,Lamotrigine
,10807660,free,"At equilibrium, the CSF to total serum concentration ratio (0.61+/-0.02) was greater than the free to total serum concentration (0.39+/-0.01).","Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10807660/),,0.39,157813,DB00555,Lamotrigine
,10807660,penetration half-time,"Using in vivo recovery corrected microdialysis sampling in frontal cortex and hippocampus with concomitant serum sampling, the calculated penetration half-time of lamotrigine into bECF, 0.51+/-0.11 h, was similar to that for CSF and was not area or dose dependent.","Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10807660/),h,0.51,157814,DB00555,Lamotrigine
,10807660,to total serum concentration ratio,"At equilibrium, the bECF to total serum concentration ratio (0.40+/-0.04) was similar to the free to total serum concentration (0.39+/-0.01), and did not differ between hippocampus and frontal cortex.","Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10807660/),,0.40,157815,DB00555,Lamotrigine
,10807660,to total serum concentration ratio,"At equilibrium, the bECF to total serum concentration ratio (0.40+/-0.04) was similar to the free to total serum concentration (0.39+/-0.01), and did not differ between hippocampus and frontal cortex.","Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10807660/),,0.39,157816,DB00555,Lamotrigine
,19132712,maximum plasma concentration,Geometric mean (GM) values for lamotrigine maximum plasma concentration were similar for lamotrigine alone (26 ng/mL) and with co-administered aripiprazole (23 ng/mL).,A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132712/),[ng] / [ml],26,159154,DB00555,Lamotrigine
,19132712,maximum plasma concentration,Geometric mean (GM) values for lamotrigine maximum plasma concentration were similar for lamotrigine alone (26 ng/mL) and with co-administered aripiprazole (23 ng/mL).,A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132712/),[ng] / [ml],23,159155,DB00555,Lamotrigine
,19132712,area under the concentration-time curve (AUCtau),GM values for plasma lamotrigine area under the concentration-time curve (AUCtau) were comparable for lamotrigine alone (434 ng/h/mL) and with co-administered aripiprazole (394 ng/h/mL).,A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132712/),[ng] / [h·ml],434,159156,DB00555,Lamotrigine
,19132712,area under the concentration-time curve (AUCtau),GM values for plasma lamotrigine area under the concentration-time curve (AUCtau) were comparable for lamotrigine alone (434 ng/h/mL) and with co-administered aripiprazole (394 ng/h/mL).,A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132712/),[ng] / [h·ml],394,159157,DB00555,Lamotrigine
,19132712,T(max),"Median T(max) of lamotrigine alone and combined with aripiprazole was 1.98 and 0.77 h, respectively.",A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132712/),h,1.98,159158,DB00555,Lamotrigine
,19132712,T(max),"Median T(max) of lamotrigine alone and combined with aripiprazole was 1.98 and 0.77 h, respectively.",A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132712/),h,0.77,159159,DB00555,Lamotrigine
,22508175,Tmax,"After oral administration of 97/78, the Tmax and Cmax values of 97/63 in male rats were 1.75±0.77 h and 862±306 ng/mL while female rats showed values for Cmax of 622.75±95.09 ng/mL and for Tmax of 7.5±0.5 h.","Intersex effect of lamotrigine on the pharmacokinetic parameters of CDRI-97/78, a novel trioxane antimalarial compound, in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22508175/),h,1.75,163558,DB00555,Lamotrigine
,22508175,Cmax,"After oral administration of 97/78, the Tmax and Cmax values of 97/63 in male rats were 1.75±0.77 h and 862±306 ng/mL while female rats showed values for Cmax of 622.75±95.09 ng/mL and for Tmax of 7.5±0.5 h.","Intersex effect of lamotrigine on the pharmacokinetic parameters of CDRI-97/78, a novel trioxane antimalarial compound, in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22508175/),[ng] / [ml],862,163559,DB00555,Lamotrigine
,22508175,Cmax,"After oral administration of 97/78, the Tmax and Cmax values of 97/63 in male rats were 1.75±0.77 h and 862±306 ng/mL while female rats showed values for Cmax of 622.75±95.09 ng/mL and for Tmax of 7.5±0.5 h.","Intersex effect of lamotrigine on the pharmacokinetic parameters of CDRI-97/78, a novel trioxane antimalarial compound, in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22508175/),[ng] / [ml],622.75,163560,DB00555,Lamotrigine
,22508175,Tmax,"After oral administration of 97/78, the Tmax and Cmax values of 97/63 in male rats were 1.75±0.77 h and 862±306 ng/mL while female rats showed values for Cmax of 622.75±95.09 ng/mL and for Tmax of 7.5±0.5 h.","Intersex effect of lamotrigine on the pharmacokinetic parameters of CDRI-97/78, a novel trioxane antimalarial compound, in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22508175/),h,7.5,163561,DB00555,Lamotrigine
,22508175,Tmax,"Coadministration of 97/78 and lamotrigine resulted in decreased Tmax and Cmax values in both male and female rats (Tmax and Cmax of 0.77±0.16 h and 58.58±6.43 ng/mL in male rats; 1.13±0.22 h and 62.95±12.00 ng/mL in female rats, respectively).","Intersex effect of lamotrigine on the pharmacokinetic parameters of CDRI-97/78, a novel trioxane antimalarial compound, in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22508175/),h,0.77,163562,DB00555,Lamotrigine
,22508175,Tmax,"Coadministration of 97/78 and lamotrigine resulted in decreased Tmax and Cmax values in both male and female rats (Tmax and Cmax of 0.77±0.16 h and 58.58±6.43 ng/mL in male rats; 1.13±0.22 h and 62.95±12.00 ng/mL in female rats, respectively).","Intersex effect of lamotrigine on the pharmacokinetic parameters of CDRI-97/78, a novel trioxane antimalarial compound, in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22508175/),h,1.13,163563,DB00555,Lamotrigine
,22508175,Cmax,"Coadministration of 97/78 and lamotrigine resulted in decreased Tmax and Cmax values in both male and female rats (Tmax and Cmax of 0.77±0.16 h and 58.58±6.43 ng/mL in male rats; 1.13±0.22 h and 62.95±12.00 ng/mL in female rats, respectively).","Intersex effect of lamotrigine on the pharmacokinetic parameters of CDRI-97/78, a novel trioxane antimalarial compound, in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22508175/),[ng] / [ml],58.58,163564,DB00555,Lamotrigine
,22508175,Cmax,"Coadministration of 97/78 and lamotrigine resulted in decreased Tmax and Cmax values in both male and female rats (Tmax and Cmax of 0.77±0.16 h and 58.58±6.43 ng/mL in male rats; 1.13±0.22 h and 62.95±12.00 ng/mL in female rats, respectively).","Intersex effect of lamotrigine on the pharmacokinetic parameters of CDRI-97/78, a novel trioxane antimalarial compound, in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22508175/),[ng] / [ml],62.95,163565,DB00555,Lamotrigine
,12510869,ED50,"Aminophylline (50-100 mg/kg) and strychnine (0.125-0.5 mg/kg) significantly raised the ED50 values of LY 300164 against maximal electroshock in mice, from 4 to 8 mg/kg (aminophylline 100 mg/kg) and from 3.6 to 11.5 mg/kg (strychnine 0.5 mg/kg).","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],4 to 8,167513,DB00555,Lamotrigine
,12510869,ED50,"Aminophylline (50-100 mg/kg) and strychnine (0.125-0.5 mg/kg) significantly raised the ED50 values of LY 300164 against maximal electroshock in mice, from 4 to 8 mg/kg (aminophylline 100 mg/kg) and from 3.6 to 11.5 mg/kg (strychnine 0.5 mg/kg).","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],3.6 to 11.5,167514,DB00555,Lamotrigine
,12510869,ED50,"Also, aminophylline (25-50 mg/kg) and strychnine (0.125-0.25 mg/kg) increased the ED50 value of lamotrigine in this test, for instance from 5.5 to 8.0 mg/kg (aminophylline 50 mg/kg) and from 5.2 to 8.9 mg/kg (strychnine 0.25 mg/kg).","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],5,167515,DB00555,Lamotrigine
,12510869,ED50,"Also, aminophylline (25-50 mg/kg) and strychnine (0.125-0.25 mg/kg) increased the ED50 value of lamotrigine in this test, for instance from 5.5 to 8.0 mg/kg (aminophylline 50 mg/kg) and from 5.2 to 8.9 mg/kg (strychnine 0.25 mg/kg).","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],5.2 to 8.9,167516,DB00555,Lamotrigine
,12510869,ED50S,"Moreover, the ED50S values of aminophylline and strychnine for the reduction of the anticonvulsant effect of LY 300164 (7 mg/kg, the dose equal to its ED97 value against maximal electroshock) were 79.9 and 0.2 mg/kg, respectively.","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],79.9,167517,DB00555,Lamotrigine
,12510869,ED50S,"Moreover, the ED50S values of aminophylline and strychnine for the reduction of the anticonvulsant effect of LY 300164 (7 mg/kg, the dose equal to its ED97 value against maximal electroshock) were 79.9 and 0.2 mg/kg, respectively.","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],0.2,167518,DB00555,Lamotrigine
,12510869,ED50,The respective ED50 values for the inhibition of the antiseizure action of lamotrigine were 40.9 and 0.2 mg/kg.,"Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],40.9,167519,DB00555,Lamotrigine
,12510869,ED50,The respective ED50 values for the inhibition of the antiseizure action of lamotrigine were 40.9 and 0.2 mg/kg.,"Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],0.2,167520,DB00555,Lamotrigine
,26815525,Detection,"Detection and quantification limits were 0.07 μg/mL and 0.21 μg/mL, respectively.",[Development and validation of a new HPLC method for determination of Lamotrigine and clinical application]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26815525/),[μg] / [ml],0.07,168097,DB00555,Lamotrigine
,26815525,quantification limits,"Detection and quantification limits were 0.07 μg/mL and 0.21 μg/mL, respectively.",[Development and validation of a new HPLC method for determination of Lamotrigine and clinical application]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26815525/),[μg] / [ml],0.21,168098,DB00555,Lamotrigine
,29200847,cumulative release rate,The cumulative release rate in vivo of LTG-loaded mixed micelles was 84.21% at 24 hours and showed more sustained release while that of LTG-loaded micelles was 80.61% at 6 hours.,mPEG-PLA/TPGS mixed micelles via intranasal administration improved the bioavailability of lamotrigine in the hippocampus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29200847/),%,84.21,168646,DB00555,Lamotrigine
,29200847,cumulative release rate,The cumulative release rate in vivo of LTG-loaded mixed micelles was 84.21% at 24 hours and showed more sustained release while that of LTG-loaded micelles was 80.61% at 6 hours.,mPEG-PLA/TPGS mixed micelles via intranasal administration improved the bioavailability of lamotrigine in the hippocampus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29200847/),%,80.61,168647,DB00555,Lamotrigine
,29200847,Tmax,"The Tmax and area under concentration-time curve from zero to time of last quantifiable concentration of LTG solution, LTG-loaded micelles, and LTG-loaded mixed micelles were 55, 35, and 15 minutes and about 5,384, 16,500, and 25,245 (min⋅μg)/L in the hippocampus, respectively.",mPEG-PLA/TPGS mixed micelles via intranasal administration improved the bioavailability of lamotrigine in the hippocampus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29200847/),min,55,168648,DB00555,Lamotrigine
,29200847,Tmax,"The Tmax and area under concentration-time curve from zero to time of last quantifiable concentration of LTG solution, LTG-loaded micelles, and LTG-loaded mixed micelles were 55, 35, and 15 minutes and about 5,384, 16,500, and 25,245 (min⋅μg)/L in the hippocampus, respectively.",mPEG-PLA/TPGS mixed micelles via intranasal administration improved the bioavailability of lamotrigine in the hippocampus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29200847/),min,35,168649,DB00555,Lamotrigine
,29200847,area under concentration-time curve from zero to time of last,"The Tmax and area under concentration-time curve from zero to time of last quantifiable concentration of LTG solution, LTG-loaded micelles, and LTG-loaded mixed micelles were 55, 35, and 15 minutes and about 5,384, 16,500, and 25,245 (min⋅μg)/L in the hippocampus, respectively.",mPEG-PLA/TPGS mixed micelles via intranasal administration improved the bioavailability of lamotrigine in the hippocampus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29200847/),min,35,168650,DB00555,Lamotrigine
,29200847,area under concentration-time curve from zero to time of last,"The Tmax and area under concentration-time curve from zero to time of last quantifiable concentration of LTG solution, LTG-loaded micelles, and LTG-loaded mixed micelles were 55, 35, and 15 minutes and about 5,384, 16,500, and 25,245 (min⋅μg)/L in the hippocampus, respectively.",mPEG-PLA/TPGS mixed micelles via intranasal administration improved the bioavailability of lamotrigine in the hippocampus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29200847/),min,15,168651,DB00555,Lamotrigine
,29200847,area under concentration-time curve from zero to time of last,"The Tmax and area under concentration-time curve from zero to time of last quantifiable concentration of LTG solution, LTG-loaded micelles, and LTG-loaded mixed micelles were 55, 35, and 15 minutes and about 5,384, 16,500, and 25,245 (min⋅μg)/L in the hippocampus, respectively.",mPEG-PLA/TPGS mixed micelles via intranasal administration improved the bioavailability of lamotrigine in the hippocampus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29200847/),[min·μg] / [l],"5,384",168652,DB00555,Lamotrigine
,29200847,area under concentration-time curve from zero to time of last,"The Tmax and area under concentration-time curve from zero to time of last quantifiable concentration of LTG solution, LTG-loaded micelles, and LTG-loaded mixed micelles were 55, 35, and 15 minutes and about 5,384, 16,500, and 25,245 (min⋅μg)/L in the hippocampus, respectively.",mPEG-PLA/TPGS mixed micelles via intranasal administration improved the bioavailability of lamotrigine in the hippocampus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29200847/),[min·μg] / [l],"16,500",168653,DB00555,Lamotrigine
,29200847,area under concentration-time curve from zero to time of last,"The Tmax and area under concentration-time curve from zero to time of last quantifiable concentration of LTG solution, LTG-loaded micelles, and LTG-loaded mixed micelles were 55, 35, and 15 minutes and about 5,384, 16,500, and 25,245 (min⋅μg)/L in the hippocampus, respectively.",mPEG-PLA/TPGS mixed micelles via intranasal administration improved the bioavailability of lamotrigine in the hippocampus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29200847/),[min·μg] / [l],"25,245",168654,DB00555,Lamotrigine
,23995050,maximum Cl/F,"Age was a significant factor contributing to pharmacokinetic variability in individuals using LTG, OXC, and CBZ with increasing clearance as a function of bioavailability (Cl/F) over age 18, a maximum Cl/F at 33years (CBZ) and 36 years (LTG and OXC), and a gradual decrease of Cl/F towards older age.",The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23995050/),years,33,170622,DB00555,Lamotrigine
,23995050,maximum Cl/F,"Age was a significant factor contributing to pharmacokinetic variability in individuals using LTG, OXC, and CBZ with increasing clearance as a function of bioavailability (Cl/F) over age 18, a maximum Cl/F at 33years (CBZ) and 36 years (LTG and OXC), and a gradual decrease of Cl/F towards older age.",The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23995050/),years,36,170623,DB00555,Lamotrigine
,19954714,clearance,"Typical mean value of lamotrigine clearance, estimated by the base model (without covariates), in our population was 1.15 l h-1.",Population pharmacokinetics of lamotrigine in patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954714/),[l] / [h],1.15,171748,DB00555,Lamotrigine
,8823232,Oral clearance,Oral clearance of valproate was increased (from 7.2 +/- 1.1 ml/hr/kg before lamotrigine treatment to 9.0 +/- 2.0 ml/hr/kg on day 28; p < 0.05).,Bidirectional interaction of valproate and lamotrigine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823232/),[ml] / [h·kg],7.2,179825,DB00555,Lamotrigine
,8823232,Oral clearance,Oral clearance of valproate was increased (from 7.2 +/- 1.1 ml/hr/kg before lamotrigine treatment to 9.0 +/- 2.0 ml/hr/kg on day 28; p < 0.05).,Bidirectional interaction of valproate and lamotrigine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823232/),[ml] / [h·kg],9.0,179826,DB00555,Lamotrigine
,1680630,volume of distribution (Vss,Lamotrigine is a low clearance drug (Cl = 2.51 +/- 0.063 ml/min/kg) with a large volume of distribution (Vss = 2.23 +/- 0.403 liter/kg).,A quaternary ammonium glucuronide is the major metabolite of lamotrigine in guinea pigs. In vitro and in vivo studies. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680630/),[l] / [kg],2.23,180298,DB00555,Lamotrigine
,1680630,half-life,The half-life of lamotrigine was 11.5 +/- 2.0 hr.,A quaternary ammonium glucuronide is the major metabolite of lamotrigine in guinea pigs. In vitro and in vivo studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680630/),h,11.5,180299,DB00555,Lamotrigine
,1680630,KM,The KM was 2.10 +/- 0.44 mM and the Vmax was 0.252 +/- 0.0312 nmol/min/mg protein in untreated microsomes.,A quaternary ammonium glucuronide is the major metabolite of lamotrigine in guinea pigs. In vitro and in vivo studies. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680630/),mM,2.10,180300,DB00555,Lamotrigine
,1680630,Vmax,The KM was 2.10 +/- 0.44 mM and the Vmax was 0.252 +/- 0.0312 nmol/min/mg protein in untreated microsomes.,A quaternary ammonium glucuronide is the major metabolite of lamotrigine in guinea pigs. In vitro and in vivo studies. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680630/),[nM] / [mg·min],0.252,180301,DB00555,Lamotrigine
,8223137,elimination half-life,The elimination half-life of lamotrigine was approximately 25 h in subjects with normal renal function and 50 h in uraemic patients.,Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223137/),h,25,184879,DB00555,Lamotrigine
,8223137,elimination half-life,The elimination half-life of lamotrigine was approximately 25 h in subjects with normal renal function and 50 h in uraemic patients.,Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223137/),h,50,184880,DB00555,Lamotrigine
,8223137,elimination half-life,Haemodialysis shortened the elimination half-life from 59.6 +/- 28.1 h during the interdialysis period to 12.2 +/- 6.4 h during the dialysis period; 17% of the dose was extracted by haemodialysis.,Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223137/),h,59.6,184881,DB00555,Lamotrigine
,8223137,elimination half-life,Haemodialysis shortened the elimination half-life from 59.6 +/- 28.1 h during the interdialysis period to 12.2 +/- 6.4 h during the dialysis period; 17% of the dose was extracted by haemodialysis.,Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223137/),h,12.2,184882,DB00555,Lamotrigine
,25903807,"time to peak concentration (Tmax, ss)","The time to peak concentration (Tmax, ss) was delayed for XR lamotrigine (3.0 vs 1.3 hours) with lower peak concentration (15% lower).",Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25903807/),h,3.0,193553,DB00555,Lamotrigine
,25903807,"time to peak concentration (Tmax, ss)","The time to peak concentration (Tmax, ss) was delayed for XR lamotrigine (3.0 vs 1.3 hours) with lower peak concentration (15% lower).",Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25903807/),h,1.3,193554,DB00555,Lamotrigine
,25903807,absolute bioavailability,"The absolute bioavailability for IR and XR formulations was 73% and 92%, respectively.",Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25903807/),%,73,193555,DB00555,Lamotrigine
,25903807,absolute bioavailability,"The absolute bioavailability for IR and XR formulations was 73% and 92%, respectively.",Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25903807/),%,92,193556,DB00555,Lamotrigine
,9169285,apparent LTG oral clearance,"There was no statistically significant differences in either apparent LTG oral clearance (0.026 +/- 0.005 vs. 0.024 +/- 0.01 l/kg per h, respectively), or in mean elimination half-life (33.7 +/- 7.5 vs. 40.2 +/- 15.05 h, respectively).",Lamotrigine pharmacokinetics in patients receiving felbamate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9169285/),[l] / [h·kg],0.026,194279,DB00555,Lamotrigine
,9169285,apparent LTG oral clearance,"There was no statistically significant differences in either apparent LTG oral clearance (0.026 +/- 0.005 vs. 0.024 +/- 0.01 l/kg per h, respectively), or in mean elimination half-life (33.7 +/- 7.5 vs. 40.2 +/- 15.05 h, respectively).",Lamotrigine pharmacokinetics in patients receiving felbamate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9169285/),[l] / [h·kg],0.024,194280,DB00555,Lamotrigine
,9169285,elimination half-life,"There was no statistically significant differences in either apparent LTG oral clearance (0.026 +/- 0.005 vs. 0.024 +/- 0.01 l/kg per h, respectively), or in mean elimination half-life (33.7 +/- 7.5 vs. 40.2 +/- 15.05 h, respectively).",Lamotrigine pharmacokinetics in patients receiving felbamate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9169285/),h,33.7,194281,DB00555,Lamotrigine
,9169285,elimination half-life,"There was no statistically significant differences in either apparent LTG oral clearance (0.026 +/- 0.005 vs. 0.024 +/- 0.01 l/kg per h, respectively), or in mean elimination half-life (33.7 +/- 7.5 vs. 40.2 +/- 15.05 h, respectively).",Lamotrigine pharmacokinetics in patients receiving felbamate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9169285/),h,40.2,194282,DB00555,Lamotrigine
below,33244764,trough concentrations,"In our cohort, 22.6% of trough concentrations were below 2.5 mg/L.",Dosing Recommendations for Lamotrigine in Children: Evaluation Based on Previous and New Population Pharmacokinetic Models. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33244764/),[mg] / [l],2.5,196464,DB00555,Lamotrigine
,10996503,plasma concentrations,LTG dose of 369+/-236 mg per day (8.1+/-5.9 mg/kg per day) achieved LTG plasma concentrations of 6.8+/-3.3 microg/ml.,Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10996503/),[μg] / [ml],6.8,196945,DB00555,Lamotrigine
,10996503,oral clearance (Cl/F),"The observed LTG monotherapy, LTG+IND, and LTG+VPA oral clearance (Cl/F) were 0. 69+/-0.2, 1.60+/-0.65 and 0.2+/-0.05 ml/kg per min, respectively.",Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10996503/),[ml] / [kg·min],0. 69,196946,DB00555,Lamotrigine
,10996503,oral clearance (Cl/F),"The observed LTG monotherapy, LTG+IND, and LTG+VPA oral clearance (Cl/F) were 0. 69+/-0.2, 1.60+/-0.65 and 0.2+/-0.05 ml/kg per min, respectively.",Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10996503/),[ml] / [kg·min],1.60,196947,DB00555,Lamotrigine
,10996503,oral clearance (Cl/F),"The observed LTG monotherapy, LTG+IND, and LTG+VPA oral clearance (Cl/F) were 0. 69+/-0.2, 1.60+/-0.65 and 0.2+/-0.05 ml/kg per min, respectively.",Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10996503/),[ml] / [kg·min],0.2,196948,DB00555,Lamotrigine
,21905057,total run time,"The total run time was 2.0 min and the elution of LAM and IS occurred at 1.25 and 1.45 min; this was achieved with a mobile phase consisting of 0.1% formic acid-methanol (20:40:40, v/v) at a flow rate of 0.50 mL/min on a Discovery CN (50 × 4.6 mm, 5 µm) column.",Rapid and sensitive LC-MS/MS method for quantification of lamotrigine in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21905057/),min,2.0,197225,DB00555,Lamotrigine
,21905057,flow rate,"The total run time was 2.0 min and the elution of LAM and IS occurred at 1.25 and 1.45 min; this was achieved with a mobile phase consisting of 0.1% formic acid-methanol (20:40:40, v/v) at a flow rate of 0.50 mL/min on a Discovery CN (50 × 4.6 mm, 5 µm) column.",Rapid and sensitive LC-MS/MS method for quantification of lamotrigine in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21905057/),[ml] / [min],0.50,197226,DB00555,Lamotrigine
,15686986,flow-rate,"Chromatographic separation was achieved on a silica column with the mobile phase of acetonitrile-water containing 0.2% phosphoric acid and 0.3% triethylamine (pH 2.7) (84:16, v/v), at a flow-rate of 1 ml/min.",Determination of lamotrigine in small volumes of plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686986/),[ml] / [min],1,197451,DB00555,Lamotrigine
,15686986,retention time,The retention time was about 6 min for lamotrigine and 7 min for guanabenz.,Determination of lamotrigine in small volumes of plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686986/),min,6,197452,DB00555,Lamotrigine
,15686986,retention time,The retention time was about 6 min for lamotrigine and 7 min for guanabenz.,Determination of lamotrigine in small volumes of plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686986/),min,7,197453,DB00555,Lamotrigine
,15686986,relative recovery,The relative recovery of lamotrigine averaged about 80%.,Determination of lamotrigine in small volumes of plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686986/),%,80,197454,DB00555,Lamotrigine
,17516704,apparent elimination half-life (t((1/2))),In plasma after a single oral administration of oxcarbazepine the mean apparent elimination half-life (t((1/2))) of MHD in adults was 8-9h.,Overview of the clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516704/),h,8-9,197924,DB00555,Lamotrigine
,17516704,ki [inhibition constant],"In vitro, MHD inhibits the cytochrome P450 (CYP) 2C19 (ki [inhibition constant] = 88 micromol/L).",Overview of the clinical pharmacokinetics of oxcarbazepine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516704/),[μM] / [l],88,197925,DB00555,Lamotrigine
,22829119,retention times,"The retention times of SMA and IS for the plasma sample were 9.2 and 4.4 min, respectively, and those for the urine samples were 7.9 and 4.3 min, respectively.",A simple and sensitive HPLC-UV determination of 7-O-succinyl macrolactin A in rat plasma and urine and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22829119/),min,9.2,200210,DB00555,Lamotrigine
,22829119,retention times,"The retention times of SMA and IS for the plasma sample were 9.2 and 4.4 min, respectively, and those for the urine samples were 7.9 and 4.3 min, respectively.",A simple and sensitive HPLC-UV determination of 7-O-succinyl macrolactin A in rat plasma and urine and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22829119/),min,4.4,200211,DB00555,Lamotrigine
,22829119,retention times,"The retention times of SMA and IS for the plasma sample were 9.2 and 4.4 min, respectively, and those for the urine samples were 7.9 and 4.3 min, respectively.",A simple and sensitive HPLC-UV determination of 7-O-succinyl macrolactin A in rat plasma and urine and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22829119/),min,7.9,200212,DB00555,Lamotrigine
,22829119,retention times,"The retention times of SMA and IS for the plasma sample were 9.2 and 4.4 min, respectively, and those for the urine samples were 7.9 and 4.3 min, respectively.",A simple and sensitive HPLC-UV determination of 7-O-succinyl macrolactin A in rat plasma and urine and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22829119/),min,4.3,200213,DB00555,Lamotrigine
,27120710,CL/F,"The lowest LTG CL/F was found in patients comedicated with valproate (VPA) (mean, 0.0183 L/h per kg), followed by patients receiving VPA + enzyme inducers (0.0271 L/h per kg), patients on LTG monotherapy (0.0298 L/h per kg) and patients comedicated with enzyme inducers (0.056 L/h per kg) LTG CL/F correlated significantly with LTG dose (P < 0.01), but showed no significant relationship with gender, weight, and age.",An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27120710/),[l] / [h·kg],0.0183,203606,DB00555,Lamotrigine
,27120710,CL/F,"The lowest LTG CL/F was found in patients comedicated with valproate (VPA) (mean, 0.0183 L/h per kg), followed by patients receiving VPA + enzyme inducers (0.0271 L/h per kg), patients on LTG monotherapy (0.0298 L/h per kg) and patients comedicated with enzyme inducers (0.056 L/h per kg) LTG CL/F correlated significantly with LTG dose (P < 0.01), but showed no significant relationship with gender, weight, and age.",An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27120710/),[l] / [h·kg],0.0271,203607,DB00555,Lamotrigine
,27120710,CL/F,"The lowest LTG CL/F was found in patients comedicated with valproate (VPA) (mean, 0.0183 L/h per kg), followed by patients receiving VPA + enzyme inducers (0.0271 L/h per kg), patients on LTG monotherapy (0.0298 L/h per kg) and patients comedicated with enzyme inducers (0.056 L/h per kg) LTG CL/F correlated significantly with LTG dose (P < 0.01), but showed no significant relationship with gender, weight, and age.",An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27120710/),[l] / [h·kg],0.0298,203608,DB00555,Lamotrigine
,27120710,CL/F,"The lowest LTG CL/F was found in patients comedicated with valproate (VPA) (mean, 0.0183 L/h per kg), followed by patients receiving VPA + enzyme inducers (0.0271 L/h per kg), patients on LTG monotherapy (0.0298 L/h per kg) and patients comedicated with enzyme inducers (0.056 L/h per kg) LTG CL/F correlated significantly with LTG dose (P < 0.01), but showed no significant relationship with gender, weight, and age.",An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27120710/),[l] / [h·kg],0.056,203609,DB00555,Lamotrigine
,9159559,CLo,"However, due to auto-induction CLo increased by 17.3% during the 48 weeks of therapy, from 1.94 to 2.28 l h(-1), and was 28.7% lower in Asians than Caucasian.",Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159559/),[l] / [h],1.94,203841,DB00555,Lamotrigine
,9159559,CLo,"However, due to auto-induction CLo increased by 17.3% during the 48 weeks of therapy, from 1.94 to 2.28 l h(-1), and was 28.7% lower in Asians than Caucasian.",Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159559/),[l] / [h],2.28,203842,DB00555,Lamotrigine
,9159559,V/F,The final population estimate of V/F was 77.4 l with an interpatient variability of 34%.,Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159559/),l,77.4,203843,DB00555,Lamotrigine
,17825077,time to peak concentration (Tmax),"The median time to peak concentration (Tmax) following administration of LTG-XR ranged from 4 to 6 h, 6 to 10 h, and 9 to 11 h in the induced, neutral, and inhibited groups, respectively.",Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825077/),h,4 to 6,206378,DB00555,Lamotrigine
,17825077,time to peak concentration (Tmax),"The median time to peak concentration (Tmax) following administration of LTG-XR ranged from 4 to 6 h, 6 to 10 h, and 9 to 11 h in the induced, neutral, and inhibited groups, respectively.",Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825077/),h,6 to 10,206379,DB00555,Lamotrigine
,17825077,time to peak concentration (Tmax),"The median time to peak concentration (Tmax) following administration of LTG-XR ranged from 4 to 6 h, 6 to 10 h, and 9 to 11 h in the induced, neutral, and inhibited groups, respectively.",Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825077/),h,9 to 11,206380,DB00555,Lamotrigine
,17825077,Tmax,"In comparison, the median Tmax following administration of LTG-IR was between 1 and 1.5 h.",Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825077/),h,1 and 1.5,206381,DB00555,Lamotrigine
,25162213,percent recovery,"Intraday and interday reproducibility were less than 10.0% relative SD and 10.4% relative SD, respectively, and the percent recovery varied from 96.6% to 109.3% at various lamotrigine concentrations.",Quantification of lamotrigine in patient plasma using a fast liquid chromatography-tandem mass spectrometry method with backflush technology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25162213/),%,96.6,207726,DB00555,Lamotrigine
,25162213,percent recovery,"Intraday and interday reproducibility were less than 10.0% relative SD and 10.4% relative SD, respectively, and the percent recovery varied from 96.6% to 109.3% at various lamotrigine concentrations.",Quantification of lamotrigine in patient plasma using a fast liquid chromatography-tandem mass spectrometry method with backflush technology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25162213/),%,109.3,207727,DB00555,Lamotrigine
,20515532,mass,The mass transition [M+H](+) ions used for detection were m/z 256.0 --> 211.0 for lamotrigine and m/z 188.0 --> 143.0 for IS.,Rapid quantification of lamotrigine in human plasma by two LC systems connected with tandem MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515532/),,256.0,207955,DB00555,Lamotrigine
,20515532,m/z,The mass transition [M+H](+) ions used for detection were m/z 256.0 --> 211.0 for lamotrigine and m/z 188.0 --> 143.0 for IS.,Rapid quantification of lamotrigine in human plasma by two LC systems connected with tandem MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515532/),,256.0,207956,DB00555,Lamotrigine
,20515532,m/z,The mass transition [M+H](+) ions used for detection were m/z 256.0 --> 211.0 for lamotrigine and m/z 188.0 --> 143.0 for IS.,Rapid quantification of lamotrigine in human plasma by two LC systems connected with tandem MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515532/),,211.0,207957,DB00555,Lamotrigine
,20515532,m/z,The mass transition [M+H](+) ions used for detection were m/z 256.0 --> 211.0 for lamotrigine and m/z 188.0 --> 143.0 for IS.,Rapid quantification of lamotrigine in human plasma by two LC systems connected with tandem MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515532/),,188.0,207958,DB00555,Lamotrigine
,20515532,m/z,The mass transition [M+H](+) ions used for detection were m/z 256.0 --> 211.0 for lamotrigine and m/z 188.0 --> 143.0 for IS.,Rapid quantification of lamotrigine in human plasma by two LC systems connected with tandem MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515532/),,143.0,207959,DB00555,Lamotrigine
,20515532,limit of detection,"The limit of quantification for lamotrigine was 0.025 microg/mL, and limit of detection was 50.000 pg/mL.",Rapid quantification of lamotrigine in human plasma by two LC systems connected with tandem MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515532/),[pg] / [ml],50.000,207960,DB00555,Lamotrigine
,20515532,overall recoveries,"The overall recoveries for lamotrigine and IS were 97.9% and 92.5%, respectively.",Rapid quantification of lamotrigine in human plasma by two LC systems connected with tandem MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515532/),%,97.9,207961,DB00555,Lamotrigine
,20515532,overall recoveries,"The overall recoveries for lamotrigine and IS were 97.9% and 92.5%, respectively.",Rapid quantification of lamotrigine in human plasma by two LC systems connected with tandem MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515532/),%,92.5,207962,DB00555,Lamotrigine
,20515532,Total MS run time,Total MS run time was 1.4 min per sample.,Rapid quantification of lamotrigine in human plasma by two LC systems connected with tandem MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515532/),[min] / [sample],1.4,207963,DB00555,Lamotrigine
,15795651,Cmin,"Steady-state dosing of ZNS did not significantly affect the mean Cmin (mean +/- SD: 2.8 +/- 1.4 vs 3.5 +/- 2.4 microg/mL), Cmax (5.1 +/- 3.0 vs 5.1 +/- 3.0 microg/mL), AUC0-12 (45.5 +/- 22.6 vs 50.3 +/- 32.1 microg.h/mL), and CL/F (2778.5 +/- 1368.5 vs 3052.1 +/- 2744.9 mL/h) of LTG measured before (day -1) and after (day 35) ZNS administration, respectively.",Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795651/),[μg] / [ml],2.8,210374,DB00555,Lamotrigine
,15795651,Cmin,"Steady-state dosing of ZNS did not significantly affect the mean Cmin (mean +/- SD: 2.8 +/- 1.4 vs 3.5 +/- 2.4 microg/mL), Cmax (5.1 +/- 3.0 vs 5.1 +/- 3.0 microg/mL), AUC0-12 (45.5 +/- 22.6 vs 50.3 +/- 32.1 microg.h/mL), and CL/F (2778.5 +/- 1368.5 vs 3052.1 +/- 2744.9 mL/h) of LTG measured before (day -1) and after (day 35) ZNS administration, respectively.",Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795651/),[μg] / [ml],3.5,210375,DB00555,Lamotrigine
,15795651,Cmax,"Steady-state dosing of ZNS did not significantly affect the mean Cmin (mean +/- SD: 2.8 +/- 1.4 vs 3.5 +/- 2.4 microg/mL), Cmax (5.1 +/- 3.0 vs 5.1 +/- 3.0 microg/mL), AUC0-12 (45.5 +/- 22.6 vs 50.3 +/- 32.1 microg.h/mL), and CL/F (2778.5 +/- 1368.5 vs 3052.1 +/- 2744.9 mL/h) of LTG measured before (day -1) and after (day 35) ZNS administration, respectively.",Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795651/),[μg] / [ml],5.1,210376,DB00555,Lamotrigine
,15795651,AUC0-12,"Steady-state dosing of ZNS did not significantly affect the mean Cmin (mean +/- SD: 2.8 +/- 1.4 vs 3.5 +/- 2.4 microg/mL), Cmax (5.1 +/- 3.0 vs 5.1 +/- 3.0 microg/mL), AUC0-12 (45.5 +/- 22.6 vs 50.3 +/- 32.1 microg.h/mL), and CL/F (2778.5 +/- 1368.5 vs 3052.1 +/- 2744.9 mL/h) of LTG measured before (day -1) and after (day 35) ZNS administration, respectively.",Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795651/),[h·μg] / [ml],45.5,210377,DB00555,Lamotrigine
,15795651,AUC0-12,"Steady-state dosing of ZNS did not significantly affect the mean Cmin (mean +/- SD: 2.8 +/- 1.4 vs 3.5 +/- 2.4 microg/mL), Cmax (5.1 +/- 3.0 vs 5.1 +/- 3.0 microg/mL), AUC0-12 (45.5 +/- 22.6 vs 50.3 +/- 32.1 microg.h/mL), and CL/F (2778.5 +/- 1368.5 vs 3052.1 +/- 2744.9 mL/h) of LTG measured before (day -1) and after (day 35) ZNS administration, respectively.",Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795651/),[h·μg] / [ml],50.3,210378,DB00555,Lamotrigine
,15795651,CL/F,"Steady-state dosing of ZNS did not significantly affect the mean Cmin (mean +/- SD: 2.8 +/- 1.4 vs 3.5 +/- 2.4 microg/mL), Cmax (5.1 +/- 3.0 vs 5.1 +/- 3.0 microg/mL), AUC0-12 (45.5 +/- 22.6 vs 50.3 +/- 32.1 microg.h/mL), and CL/F (2778.5 +/- 1368.5 vs 3052.1 +/- 2744.9 mL/h) of LTG measured before (day -1) and after (day 35) ZNS administration, respectively.",Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795651/),[ml] / [h],2778.5,210379,DB00555,Lamotrigine
,15795651,CL/F,"Steady-state dosing of ZNS did not significantly affect the mean Cmin (mean +/- SD: 2.8 +/- 1.4 vs 3.5 +/- 2.4 microg/mL), Cmax (5.1 +/- 3.0 vs 5.1 +/- 3.0 microg/mL), AUC0-12 (45.5 +/- 22.6 vs 50.3 +/- 32.1 microg.h/mL), and CL/F (2778.5 +/- 1368.5 vs 3052.1 +/- 2744.9 mL/h) of LTG measured before (day -1) and after (day 35) ZNS administration, respectively.",Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795651/),[ml] / [h],3052.1,210380,DB00555,Lamotrigine
,9656165,flow rate,"The drug and the internal standard (chloramphenicol) were eluted from a Symmetry C18 stainless steel column at ambient temperature with a mobile phase consisting of 0.01 M potassium-acetonitrile-methanol (70.20:10% v/v/v), adjusted to pH 6.7, at a flow rate of 1.3 ml min-1 and the detector was monitored at 214 nm.",A rapid liquid chromatographic method for the determination of lamotrigine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9656165/),[ml] / [min],1.3,211706,DB00555,Lamotrigine
,9656165,peak-area ratio,Quantitation was achieved by measurement of the peak-area ratio of the drug to the internal standard and the lower limit of detection for lamotrigine in plasma was 20 ng ml-1.,A rapid liquid chromatographic method for the determination of lamotrigine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9656165/),[ng] / [ml],20,211707,DB00555,Lamotrigine
,9656165,absolute,"The absolute and relative recoveries of lamotrigine ranged from 86.93 to 90.71% and from 95.18 to 107.13%, respectively.",A rapid liquid chromatographic method for the determination of lamotrigine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9656165/),%,86.93 to 90.71,211708,DB00555,Lamotrigine
,9656165,relative recoveries,"The absolute and relative recoveries of lamotrigine ranged from 86.93 to 90.71% and from 95.18 to 107.13%, respectively.",A rapid liquid chromatographic method for the determination of lamotrigine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9656165/),%,95.18 to 107.13,211709,DB00555,Lamotrigine
,34002327,UAR,"UAR was 0.18-0.44 when mothers received 200 mg lamotrigine, suggesting that infants can receive 18-44% of the exposure per dose as compared to adults.",Incorporating Breastfeeding-Related Variability with Physiologically Based Pharmacokinetic Modeling to Predict Infant Exposure to Maternal Medication Through Breast Milk: a Workflow Applied to Lamotrigine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34002327/),,0.18-0.44,215737,DB00555,Lamotrigine
,30169477,apparent clearance (CL/F),"In the final model, apparent clearance (CL/F) of LTG was estimated to be 1.48 L/h; 500 mg valproic acid, oxcarbazepine, and UGT2B7-161TT genotype changed the CL/F by -46.2, +31.1, and -21.8%, respectively.",A Population Pharmacokinetic-Pharmacogenetic Model of Lamotrigine in Chinese Children With Epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30169477/),[l] / [h],1.48,216020,DB00555,Lamotrigine
,7698101,half-life,CBZ-E pharmacokinetic parameters in LTG-treated patients were found to be similar to those observed in controls (half-life: 7.2 +/- 1.6 vs 6.1 +/- 0.9 h; apparent oral clearance: 110.8 +/- 53.1 vs 120.5 +/- 29.9 ml/h/kg; apparent volume of distribution: 1.08 +/- 0.37 vs 1.04 +/- 0.25 l/kg respectively; means +/- s.d.).,"Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7698101/),h,7.2,220124,DB00555,Lamotrigine
,7698101,half-life,CBZ-E pharmacokinetic parameters in LTG-treated patients were found to be similar to those observed in controls (half-life: 7.2 +/- 1.6 vs 6.1 +/- 0.9 h; apparent oral clearance: 110.8 +/- 53.1 vs 120.5 +/- 29.9 ml/h/kg; apparent volume of distribution: 1.08 +/- 0.37 vs 1.04 +/- 0.25 l/kg respectively; means +/- s.d.).,"Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7698101/),h,6.1,220125,DB00555,Lamotrigine
,7698101,apparent oral clearance,CBZ-E pharmacokinetic parameters in LTG-treated patients were found to be similar to those observed in controls (half-life: 7.2 +/- 1.6 vs 6.1 +/- 0.9 h; apparent oral clearance: 110.8 +/- 53.1 vs 120.5 +/- 29.9 ml/h/kg; apparent volume of distribution: 1.08 +/- 0.37 vs 1.04 +/- 0.25 l/kg respectively; means +/- s.d.).,"Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7698101/),[ml] / [h·kg],110.8,220126,DB00555,Lamotrigine
,7698101,apparent oral clearance,CBZ-E pharmacokinetic parameters in LTG-treated patients were found to be similar to those observed in controls (half-life: 7.2 +/- 1.6 vs 6.1 +/- 0.9 h; apparent oral clearance: 110.8 +/- 53.1 vs 120.5 +/- 29.9 ml/h/kg; apparent volume of distribution: 1.08 +/- 0.37 vs 1.04 +/- 0.25 l/kg respectively; means +/- s.d.).,"Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7698101/),[ml] / [h·kg],120.5,220127,DB00555,Lamotrigine
,7698101,apparent volume of distribution,CBZ-E pharmacokinetic parameters in LTG-treated patients were found to be similar to those observed in controls (half-life: 7.2 +/- 1.6 vs 6.1 +/- 0.9 h; apparent oral clearance: 110.8 +/- 53.1 vs 120.5 +/- 29.9 ml/h/kg; apparent volume of distribution: 1.08 +/- 0.37 vs 1.04 +/- 0.25 l/kg respectively; means +/- s.d.).,"Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7698101/),[l] / [kg],1.08,220128,DB00555,Lamotrigine
,7698101,apparent volume of distribution,CBZ-E pharmacokinetic parameters in LTG-treated patients were found to be similar to those observed in controls (half-life: 7.2 +/- 1.6 vs 6.1 +/- 0.9 h; apparent oral clearance: 110.8 +/- 53.1 vs 120.5 +/- 29.9 ml/h/kg; apparent volume of distribution: 1.08 +/- 0.37 vs 1.04 +/- 0.25 l/kg respectively; means +/- s.d.).,"Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7698101/),[l] / [kg],1.04,220129,DB00555,Lamotrigine
,21083187,maximum plasma concentration,Mean maximum plasma concentration was 1.37 µg/ml and was reached at 1.6 h postdose.,Development of an ultra-performance liquid chromatography-tandem mass spectrometry micromethod for quantification of lamotrigine in human plasma and its use in a bioequivalence trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21083187/),[μg] / [ml],1.37,220295,DB00555,Lamotrigine
,21083187,Elimination half-life,Elimination half-life was 32.7 h.,Development of an ultra-performance liquid chromatography-tandem mass spectrometry micromethod for quantification of lamotrigine in human plasma and its use in a bioequivalence trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21083187/),h,32.7,220296,DB00555,Lamotrigine
,27697728,flow rate,"The chromatographic resolution of LTG and chloramphenicol, used as internal standard (IS), was accomplished in less than 5min on a C18 column, at 35°C, using an isocratic elution with acetonitrile (13%), methanol (13%) and water-triethylamine (99.7:0.3, v/v; pH 6.0) pumped at a flow rate of 1mL/min.",An easy-to-use liquid chromatography assay for the analysis of lamotrigine in rat plasma and brain samples using microextraction by packed sorbent: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27697728/),[ml] / [min],1,222234,DB00555,Lamotrigine
,27697728,absolute recovery,"LTG was extracted from rat plasma and brain homogenate samples with an average absolute recovery ranging from 68.0 to 86.7%, and its stability was demonstrated in the assayed conditions.",An easy-to-use liquid chromatography assay for the analysis of lamotrigine in rat plasma and brain samples using microextraction by packed sorbent: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27697728/),%,68.0 to 86.7,222235,DB00555,Lamotrigine
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],4.58,224633,DB00555,Lamotrigine
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],60.95,224634,DB00555,Lamotrigine
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],48.79,224635,DB00555,Lamotrigine
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],3.01,224636,DB00555,Lamotrigine
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],41.68,224637,DB00555,Lamotrigine
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],37.28,224638,DB00555,Lamotrigine
,34255318,total clearance,The population mean value of lamotrigine total clearance generated in the final model (with covariates) was 2.12 L/hr.,Population Pharmacokinetics Modeling of Lamotrigine in Jordanian Epileptic Patients Using Dried Blood Spot Sampling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34255318/),[l] / [h],2.12,226356,DB00555,Lamotrigine
,15013050,trough VPA concentrations,"Mean trough VPA concentrations at doses of 125, 250, 375 and 500 mg per day were 6.5, 13.9, 16.1 and 31.9 microg/ml, respectively.",Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15013050/),[μg] / [ml],6.5,226806,DB00555,Lamotrigine
,15013050,trough VPA concentrations,"Mean trough VPA concentrations at doses of 125, 250, 375 and 500 mg per day were 6.5, 13.9, 16.1 and 31.9 microg/ml, respectively.",Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15013050/),[μg] / [ml],13.9,226807,DB00555,Lamotrigine
,15013050,trough VPA concentrations,"Mean trough VPA concentrations at doses of 125, 250, 375 and 500 mg per day were 6.5, 13.9, 16.1 and 31.9 microg/ml, respectively.",Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15013050/),[μg] / [ml],16.1,226808,DB00555,Lamotrigine
,15013050,trough VPA concentrations,"Mean trough VPA concentrations at doses of 125, 250, 375 and 500 mg per day were 6.5, 13.9, 16.1 and 31.9 microg/ml, respectively.",Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15013050/),[μg] / [ml],31.9,226809,DB00555,Lamotrigine
,15013050,EC50 concentration,"Maximal theoretical inhibition of LTG oral clearance by VPA is approximately 65%, with an EC50 concentration value of approximately 5.6 microg/ml of VPA.",Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15013050/),[μg] / [ml],5.6,226810,DB00555,Lamotrigine
,8827398,half-life,"When used as a monotherapy, topiramate is eliminated primarily in the urine in an unchanged form with a half-life of 20 to 30 hours; elimination is faster in patients receiving concurrent medication with enzyme-inducing anticonvulsants, in whom the extent of biotransformation becomes more prominent.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,20 to 30,232847,DB00555,Lamotrigine
,8827398,half-life,"It is rapidly absorbed, 50% bound to plasma proteins and is eliminated predominantly by biotransformation; zonisamide has a half-life of 50 to 70 hours in monotherapy patients, or 25 to 35 hours in patients comedicated with enzyme-inducing anticonvulsants.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,50 to 70,232848,DB00555,Lamotrigine
,8827398,half-life,"It is rapidly absorbed, 50% bound to plasma proteins and is eliminated predominantly by biotransformation; zonisamide has a half-life of 50 to 70 hours in monotherapy patients, or 25 to 35 hours in patients comedicated with enzyme-inducing anticonvulsants.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,25 to 35,232849,DB00555,Lamotrigine
,8827398,half-life,"It is highly (96%) bound to plasma proteins and it is eliminated primarily by cytochrome P450 3A-mediated oxidation, with a half-life of about 7 hours in healthy volunteers.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,7,232850,DB00555,Lamotrigine
,14695035,Saliva:serum concentration ratios,Saliva:serum concentration ratios ranged from 0.41-1.26 (mean +/- SD 0.62 +/- 0.19) for reference laboratory A and from 0.40-1.19 ((mean +/- SD 0.64 +/- 0.18) for reference laboratory B.,Correlation of lamotrigine concentrations between serum and saliva. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14695035/),,0.41-1.26,235688,DB00555,Lamotrigine
,14695035,Saliva:serum concentration ratios,Saliva:serum concentration ratios ranged from 0.41-1.26 (mean +/- SD 0.62 +/- 0.19) for reference laboratory A and from 0.40-1.19 ((mean +/- SD 0.64 +/- 0.18) for reference laboratory B.,Correlation of lamotrigine concentrations between serum and saliva. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14695035/),,0.62,235689,DB00555,Lamotrigine
,14695035,Saliva:serum concentration ratios,Saliva:serum concentration ratios ranged from 0.41-1.26 (mean +/- SD 0.62 +/- 0.19) for reference laboratory A and from 0.40-1.19 ((mean +/- SD 0.64 +/- 0.18) for reference laboratory B.,Correlation of lamotrigine concentrations between serum and saliva. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14695035/),,0.64,235690,DB00555,Lamotrigine
,10197296,apparent oral clearance,The population mean apparent oral clearance of lamotrigine in adult patients receiving one concomitant enzyme-inducing antiepileptic drug and not valproic acid was estimated to be 1 mL/min/kg.,Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10197296/),[ml] / [kg·min],1,241375,DB00555,Lamotrigine
,26588196,steady-state area under the plasma concentration-time curve,"Co-administration of lamotrigine and paracetamol decreased the steady-state area under the plasma concentration-time curve of lamotrigine by 20% (95% CI 10%, 25%; P < 0.001) from 166 to 127 μmol l(-1) .",Paracetamol decreases steady-state exposure to lamotrigine by induction of glucuronidation in healthy subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26588196/),[μM] / [l],166,243835,DB00555,Lamotrigine
,26588196,steady-state area under the plasma concentration-time curve,"Co-administration of lamotrigine and paracetamol decreased the steady-state area under the plasma concentration-time curve of lamotrigine by 20% (95% CI 10%, 25%; P < 0.001) from 166 to 127 μmol l(-1) .",Paracetamol decreases steady-state exposure to lamotrigine by induction of glucuronidation in healthy subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26588196/),[μM] / [l],127,243836,DB00555,Lamotrigine
,26588196,formation clearance,"Concomitant administration of paracetamol increased the formation clearance of lamotrigine glucuronide conjugates by 45% (95% CI 18%, 79%, P = 0.005) from 1.7 to 2.8 l h(-1) , while the trough value of lamotrigine was reduced by 25% (95% CI 12%, 36%, P = 0.003) from 5.3 to 3.9 μmol l(-1) .",Paracetamol decreases steady-state exposure to lamotrigine by induction of glucuronidation in healthy subjects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26588196/),[l] / [h],1,243837,DB00555,Lamotrigine
,26588196,trough,"Concomitant administration of paracetamol increased the formation clearance of lamotrigine glucuronide conjugates by 45% (95% CI 18%, 79%, P = 0.005) from 1.7 to 2.8 l h(-1) , while the trough value of lamotrigine was reduced by 25% (95% CI 12%, 36%, P = 0.003) from 5.3 to 3.9 μmol l(-1) .",Paracetamol decreases steady-state exposure to lamotrigine by induction of glucuronidation in healthy subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26588196/),[μM] / [l],5.3,243838,DB00555,Lamotrigine
,26588196,trough,"Concomitant administration of paracetamol increased the formation clearance of lamotrigine glucuronide conjugates by 45% (95% CI 18%, 79%, P = 0.005) from 1.7 to 2.8 l h(-1) , while the trough value of lamotrigine was reduced by 25% (95% CI 12%, 36%, P = 0.003) from 5.3 to 3.9 μmol l(-1) .",Paracetamol decreases steady-state exposure to lamotrigine by induction of glucuronidation in healthy subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26588196/),[μM] / [l],3,243839,DB00555,Lamotrigine
,29403800,flow rate,"Chromatographic separation was performed on a Chromolith® SpeedROD; RP-18e column (50-4.6 mm i.d.) using acetonitrile: 5±0.1 mM ammonium formate solution (90:10, v/v) as the mobile phase at a flow rate of 0.500 mL/min.",Liquid chromatography tandem mass spectrometry method for the estimation of lamotrigine in human plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403800/),[ml] / [min],0.500,247032,DB00555,Lamotrigine
,29360159,effective dose,"JNJ-46356479 was active in the 6-Hz model at both 32-mA and 44-mA stimulus intensities (median effective dose = 2.8 and 10.2 mg/kg, respectively).",Potent and selective pharmacodynamic synergy between the metabotropic glutamate receptor subtype 2-positive allosteric modulator JNJ-46356479 and levetiracetam in the mouse 6-Hz (44-mA) model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29360159/),[mg] / [kg],2.8,248859,DB00555,Lamotrigine
,29360159,effective dose,"JNJ-46356479 was active in the 6-Hz model at both 32-mA and 44-mA stimulus intensities (median effective dose = 2.8 and 10.2 mg/kg, respectively).",Potent and selective pharmacodynamic synergy between the metabotropic glutamate receptor subtype 2-positive allosteric modulator JNJ-46356479 and levetiracetam in the mouse 6-Hz (44-mA) model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29360159/),[mg] / [kg],10.2,248860,DB00555,Lamotrigine
,10897156,area under the curve,The average area under the curve was 28.90 +/- 9.5 microg/mL/hr after rectal administration and 51.71 +/- 19.2 microg/mL/hr after oral administration.,Rectal absorption of lamotrigine compressed tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10897156/),[μg] / [h·ml],28.90,249344,DB00555,Lamotrigine
,10897156,area under the curve,The average area under the curve was 28.90 +/- 9.5 microg/mL/hr after rectal administration and 51.71 +/- 19.2 microg/mL/hr after oral administration.,Rectal absorption of lamotrigine compressed tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10897156/),[μg] / [h·ml],51.71,249345,DB00555,Lamotrigine
,10897156,maximum LTG concentration,The average maximum LTG concentration was 0.53 +/- 0.14 microg/mL after rectal administration and 1.45 +/- 0.35 microg/mL after oral administration.,Rectal absorption of lamotrigine compressed tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10897156/),[μg] / [ml],0.53,249346,DB00555,Lamotrigine
,10897156,maximum LTG concentration,The average maximum LTG concentration was 0.53 +/- 0.14 microg/mL after rectal administration and 1.45 +/- 0.35 microg/mL after oral administration.,Rectal absorption of lamotrigine compressed tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10897156/),[μg] / [ml],1.45,249347,DB00555,Lamotrigine
,10897156,relative bioavailability,The relative bioavailability for LTG compressed tablets was 0.63 +/- 0.33 for rectal administration.,Rectal absorption of lamotrigine compressed tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10897156/),,0.63,249348,DB00555,Lamotrigine
,18591203,milk/plasma ratio,The mean milk/plasma ratio was 41.3%.,Lamotrigine in breast milk and nursing infants: determination of exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18591203/),%,41.3,249447,DB00555,Lamotrigine
,25380628,CL/F,Typical value of PB CL/F for final model was estimated at 0.314 l/h.,Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25380628/),[l] / [h],0.314,249519,DB00555,Lamotrigine
,29340733,oral clearance (CL/F),"For the final model, the oral clearance (CL/F) of LTG was estimated to be 0.705 L/h with inter-individual variability (IIV) of 21.3%.",Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29340733/),[l] / [h],0.705,249880,DB00555,Lamotrigine
,27161345,flow rate,The flow rate was 1.50 mL/min.,"Simultaneous quantitation of the diastereoisomers of scholarisine and 19-epischolarisine, vallesamine, and picrinine in rat plasma by supercritical fluid chromatography with tandem mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27161345/),[ml] / [min],1.50,253982,DB00555,Lamotrigine
,24571554,clearance,Mean study population value of LTG clearance estimated by the final model was 3.17 l/h.,Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],3.17,259257,DB00555,Lamotrigine
,24571554,clearance,"A significant influence of OC comedication on LTG clearance was seen in both LTG monotherapy (clearance with OC 4.02±0.38 l/h, OC-free week 3.03±0.39 l/h) and in LTG-CBZ combination (clearance with OC 4.95±0.15 l/h, OC-free week 4.15±0.26 l/h).",Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],4.02,259258,DB00555,Lamotrigine
,24571554,clearance,"A significant influence of OC comedication on LTG clearance was seen in both LTG monotherapy (clearance with OC 4.02±0.38 l/h, OC-free week 3.03±0.39 l/h) and in LTG-CBZ combination (clearance with OC 4.95±0.15 l/h, OC-free week 4.15±0.26 l/h).",Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],3.03,259259,DB00555,Lamotrigine
,24571554,clearance,"A significant influence of OC comedication on LTG clearance was seen in both LTG monotherapy (clearance with OC 4.02±0.38 l/h, OC-free week 3.03±0.39 l/h) and in LTG-CBZ combination (clearance with OC 4.95±0.15 l/h, OC-free week 4.15±0.26 l/h).",Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],4.95,259260,DB00555,Lamotrigine
,24571554,clearance,"A significant influence of OC comedication on LTG clearance was seen in both LTG monotherapy (clearance with OC 4.02±0.38 l/h, OC-free week 3.03±0.39 l/h) and in LTG-CBZ combination (clearance with OC 4.95±0.15 l/h, OC-free week 4.15±0.26 l/h).",Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],4.15,259261,DB00555,Lamotrigine
,24571554,clearance,"No influence of OC was found in LTG-VPA combination (clearance with OC 0.99±0.16 l/h, OC-free week 0.90±0.15 l/h).",Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],0.99,259262,DB00555,Lamotrigine
,24571554,clearance,"No influence of OC was found in LTG-VPA combination (clearance with OC 0.99±0.16 l/h, OC-free week 0.90±0.15 l/h).",Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],0.90,259263,DB00555,Lamotrigine
,8422853,plasma CBZ,"During the controlled study, mean plasma CBZ concentrations at 2 and 6.5 h after the 600-mg dose were 5.28 and 5.36 micrograms/ml; after LTG 300 mg, they were 3.16 and 3.00 micrograms/ml.",Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422853/),[μg] / [ml],5.28,260613,DB00555,Lamotrigine
,8422853,plasma CBZ,"During the controlled study, mean plasma CBZ concentrations at 2 and 6.5 h after the 600-mg dose were 5.28 and 5.36 micrograms/ml; after LTG 300 mg, they were 3.16 and 3.00 micrograms/ml.",Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422853/),[μg] / [ml],5.36,260614,DB00555,Lamotrigine
,8422853,plasma CBZ,"During the controlled study, mean plasma CBZ concentrations at 2 and 6.5 h after the 600-mg dose were 5.28 and 5.36 micrograms/ml; after LTG 300 mg, they were 3.16 and 3.00 micrograms/ml.",Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422853/),[μg] / [ml],3.16,260615,DB00555,Lamotrigine
,8422853,plasma CBZ,"During the controlled study, mean plasma CBZ concentrations at 2 and 6.5 h after the 600-mg dose were 5.28 and 5.36 micrograms/ml; after LTG 300 mg, they were 3.16 and 3.00 micrograms/ml.",Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422853/),[μg] / [ml],3.00,260616,DB00555,Lamotrigine
,8422853,concentrations,"During the controlled study, mean plasma CBZ concentrations at 2 and 6.5 h after the 600-mg dose were 5.28 and 5.36 micrograms/ml; after LTG 300 mg, they were 3.16 and 3.00 micrograms/ml.",Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422853/),[μg] / [ml],5.28,260617,DB00555,Lamotrigine
,8422853,concentrations,"During the controlled study, mean plasma CBZ concentrations at 2 and 6.5 h after the 600-mg dose were 5.28 and 5.36 micrograms/ml; after LTG 300 mg, they were 3.16 and 3.00 micrograms/ml.",Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422853/),[μg] / [ml],5.36,260618,DB00555,Lamotrigine
,8422853,concentrations,"During the controlled study, mean plasma CBZ concentrations at 2 and 6.5 h after the 600-mg dose were 5.28 and 5.36 micrograms/ml; after LTG 300 mg, they were 3.16 and 3.00 micrograms/ml.",Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422853/),[μg] / [ml],3.16,260619,DB00555,Lamotrigine
,8422853,concentrations,"During the controlled study, mean plasma CBZ concentrations at 2 and 6.5 h after the 600-mg dose were 5.28 and 5.36 micrograms/ml; after LTG 300 mg, they were 3.16 and 3.00 micrograms/ml.",Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422853/),[μg] / [ml],3.00,260620,DB00555,Lamotrigine
,29460901,Cssmin,"In patients who used LTG in monotherapy, LTG Cssmin was 5.6±4.65 mg/l, Cssmax 7.59±5.54 mg/l.",[The clinical significance of the lamotrigine pharmacokinetic variability]. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29460901/),[mg] / [l],5.6,261732,DB00555,Lamotrigine
,29460901,Cssmax,"In patients who used LTG in monotherapy, LTG Cssmin was 5.6±4.65 mg/l, Cssmax 7.59±5.54 mg/l.",[The clinical significance of the lamotrigine pharmacokinetic variability]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29460901/),[mg] / [l],7.59,261733,DB00555,Lamotrigine
,29460901,Сssmin,"In the group that received LTG in combination with valproate, LTG Сssmin was 7.8 [5.4; 11.8] mg / l and Cssmax 11.4 [7.3; 15.3] mg/l.",[The clinical significance of the lamotrigine pharmacokinetic variability]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29460901/),[mg] / [l],7.8,261734,DB00555,Lamotrigine
,29460901,Cssmax,"In the group that received LTG in combination with valproate, LTG Сssmin was 7.8 [5.4; 11.8] mg / l and Cssmax 11.4 [7.3; 15.3] mg/l.",[The clinical significance of the lamotrigine pharmacokinetic variability]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29460901/),[mg] / [l],11.4,261735,DB00555,Lamotrigine
,29460901,Cssmin,"In the group that received LTG in combination with drug-inducers of glucuronidation, Cssmin was 2.5 [1.99; 4.32] mg/l, Cssmax 4.73 [2.91; 6.70] mg/l.",[The clinical significance of the lamotrigine pharmacokinetic variability]. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29460901/),[mg] / [l],2.5,261736,DB00555,Lamotrigine
,29460901,Cssmax,"In the group that received LTG in combination with drug-inducers of glucuronidation, Cssmin was 2.5 [1.99; 4.32] mg/l, Cssmax 4.73 [2.91; 6.70] mg/l.",[The clinical significance of the lamotrigine pharmacokinetic variability]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29460901/),[mg] / [l],4.73,261737,DB00555,Lamotrigine
,8730979,half-lives,"The half-lives (mean +/- s.d.) were: 7.7 +/- 1.8 h, 21.9 +/- 6.8 h, 44.7 +/- 10.2 h in the ""inducer', ""other' and ""inhibitor' groups respectively.",Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730979/),h,7.7,266368,DB00555,Lamotrigine
,8730979,half-lives,"The half-lives (mean +/- s.d.) were: 7.7 +/- 1.8 h, 21.9 +/- 6.8 h, 44.7 +/- 10.2 h in the ""inducer', ""other' and ""inhibitor' groups respectively.",Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730979/),h,21.9,266369,DB00555,Lamotrigine
,8730979,half-lives,"The half-lives (mean +/- s.d.) were: 7.7 +/- 1.8 h, 21.9 +/- 6.8 h, 44.7 +/- 10.2 h in the ""inducer', ""other' and ""inhibitor' groups respectively.",Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730979/),h,44.7,266370,DB00555,Lamotrigine
,8730979,minimum plasma concentration,"4. Patients were then dosed to steady state, with the dosage adjusted on the basis of the single dose pharmacokinetics to achieve a minimum plasma concentration between 1.5 and 3 mg l-1.",Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730979/),[mg] / [l],1.5 and 3,266371,DB00555,Lamotrigine
,8730979,minimum plasma concentration,The mean minimum plasma concentration for the three groups was 2.54 +/- 1.28 mg l-1 at steady state.,Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730979/),[mg] / [l],2.54,266372,DB00555,Lamotrigine
,16871388,clearance (CL),"The obtained estimates for clearance (CL) (L/h/kg) [0.075+/-0.029 (Group 1), 0.014+/-0.005 (Group 2), 0.025+/-0.008 (Group 3) and 0.044+/-0.011 (Group 4)] appear to be the most appropriate set to be implemented in clinical practice as prior information, as demonstrated by the accuracy and precision of the measurements.",Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16871388/),[l] / [h·kg],0.075,268279,DB00555,Lamotrigine
,16871388,clearance (CL),"The obtained estimates for clearance (CL) (L/h/kg) [0.075+/-0.029 (Group 1), 0.014+/-0.005 (Group 2), 0.025+/-0.008 (Group 3) and 0.044+/-0.011 (Group 4)] appear to be the most appropriate set to be implemented in clinical practice as prior information, as demonstrated by the accuracy and precision of the measurements.",Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16871388/),[l] / [h·kg],0.014,268280,DB00555,Lamotrigine
,16871388,clearance (CL),"The obtained estimates for clearance (CL) (L/h/kg) [0.075+/-0.029 (Group 1), 0.014+/-0.005 (Group 2), 0.025+/-0.008 (Group 3) and 0.044+/-0.011 (Group 4)] appear to be the most appropriate set to be implemented in clinical practice as prior information, as demonstrated by the accuracy and precision of the measurements.",Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16871388/),[l] / [h·kg],0.025,268281,DB00555,Lamotrigine
,16871388,clearance (CL),"The obtained estimates for clearance (CL) (L/h/kg) [0.075+/-0.029 (Group 1), 0.014+/-0.005 (Group 2), 0.025+/-0.008 (Group 3) and 0.044+/-0.011 (Group 4)] appear to be the most appropriate set to be implemented in clinical practice as prior information, as demonstrated by the accuracy and precision of the measurements.",Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16871388/),[l] / [h·kg],0.044,268282,DB00555,Lamotrigine
,16637792,time to reach maximum concentration,"For lamotrigine, the mean time to reach maximum concentration was significantly prolonged during olanzapine coadministration (mean +/- SD 1.9 +/- 1.3 vs 4.0 +/- 3.0 hrs, p = 0.025), possibly because of the anticholinergic properties associated with olanzapine.",Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16637792/),h,1.9,271319,DB00555,Lamotrigine
,16637792,time to reach maximum concentration,"For lamotrigine, the mean time to reach maximum concentration was significantly prolonged during olanzapine coadministration (mean +/- SD 1.9 +/- 1.3 vs 4.0 +/- 3.0 hrs, p = 0.025), possibly because of the anticholinergic properties associated with olanzapine.",Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16637792/),h,4.0,271320,DB00555,Lamotrigine
,12915337,half-life,"Although its half-life is relatively short (6 to 8 hours), its duration of action is longer than anticipated from its pharmacokinetics in plasma, and a twice-daily dosing regimen is adequate to produce the desired response.",The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915337/),h,6 to 8,271378,DB00555,Lamotrigine
,17038872,plasma concentrations,"The mean plasma concentrations of olanzapine were 31 +/- 7 ng/mL at baseline, 32 +/- 7 ng/mL at week 6, and 36 +/- 9 ng/mL at week 10, the difference between week 10 and baseline being statistically significant (P < 0.05).","Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038872/),[ng] / [ml],31,272547,DB00555,Lamotrigine
,17038872,plasma concentrations,"The mean plasma concentrations of olanzapine were 31 +/- 7 ng/mL at baseline, 32 +/- 7 ng/mL at week 6, and 36 +/- 9 ng/mL at week 10, the difference between week 10 and baseline being statistically significant (P < 0.05).","Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038872/),[ng] / [ml],32,272548,DB00555,Lamotrigine
,17038872,plasma concentrations,"The mean plasma concentrations of olanzapine were 31 +/- 7 ng/mL at baseline, 32 +/- 7 ng/mL at week 6, and 36 +/- 9 ng/mL at week 10, the difference between week 10 and baseline being statistically significant (P < 0.05).","Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038872/),[ng] / [ml],36,272549,DB00555,Lamotrigine
,10217336,concentration/dose (C/D) ratio,"In 20 patients in monotherapy, the concentration/dose (C/D) ratio was 65 (range: 50-84) nmol/L/mg (mean and 95% confidence interval, antilog from lognormal distribution).",Lamotrigine drug interactions in a TDM material. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217336/),[nM] / [l·mg],65,272553,DB00555,Lamotrigine
less,10217336,C/D ratio,"In 37 patients with concomitant carbamazepine treatment, the C/D ratio was less than half that of the patients in monotherapy; 31 (2146) nmol/L/mg, and in 14 patients with phenytoin, it was even lower; 17 (13-23) nmol/L/mg.",Lamotrigine drug interactions in a TDM material. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217336/),[nM] / [l·mg],31,272554,DB00555,Lamotrigine
,10217336,C/D ratio,"In 37 patients with concomitant carbamazepine treatment, the C/D ratio was less than half that of the patients in monotherapy; 31 (2146) nmol/L/mg, and in 14 patients with phenytoin, it was even lower; 17 (13-23) nmol/L/mg.",Lamotrigine drug interactions in a TDM material. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217336/),[nM] / [l·mg],17,272555,DB00555,Lamotrigine
,10217336,C/D,Valproic acid significantly increased the C/D to 251 (200-320) nmol/L/mg in 13 patients.,Lamotrigine drug interactions in a TDM material. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217336/),[nM] / [l·mg],251,272556,DB00555,Lamotrigine
,25599034,Tmax,The best formulation has shown Tmax of 0.5 h which was highly significant (P < 0.05) when compared with pure drug and marketed formulation.,In vitro and in vivo evaluation of fast-dissolving tablets containing solid dispersion of lamotrigine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25599034/),h,0.5,274025,DB00555,Lamotrigine
